WO1996005863A1 - Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation - Google Patents
Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation Download PDFInfo
- Publication number
- WO1996005863A1 WO1996005863A1 PCT/BE1995/000076 BE9500076W WO9605863A1 WO 1996005863 A1 WO1996005863 A1 WO 1996005863A1 BE 9500076 W BE9500076 W BE 9500076W WO 9605863 A1 WO9605863 A1 WO 9605863A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- leu
- ala
- dnr
- cells
- compound according
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract description 68
- 239000008194 pharmaceutical composition Substances 0.000 title claims description 12
- 239000003814 drug Substances 0.000 claims abstract description 55
- 239000003446 ligand Substances 0.000 claims abstract description 47
- 229940124597 therapeutic agent Drugs 0.000 claims abstract description 44
- 239000003550 marker Substances 0.000 claims abstract description 27
- 210000004369 blood Anatomy 0.000 claims abstract description 14
- 239000008280 blood Substances 0.000 claims abstract description 14
- 210000002966 serum Anatomy 0.000 claims abstract description 9
- 210000004027 cell Anatomy 0.000 claims description 119
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 claims description 92
- 229960000975 daunorubicin Drugs 0.000 claims description 84
- STQGQHZAVUOBTE-UHFFFAOYSA-N 7-Cyan-hept-2t-en-4,6-diinsaeure Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)=O)CC1OC1CC(N)C(O)C(C)O1 STQGQHZAVUOBTE-UHFFFAOYSA-N 0.000 claims description 76
- STQGQHZAVUOBTE-VGBVRHCVSA-N daunorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 STQGQHZAVUOBTE-VGBVRHCVSA-N 0.000 claims description 75
- 229960004679 doxorubicin Drugs 0.000 claims description 57
- 206010028980 Neoplasm Diseases 0.000 claims description 31
- 229940045799 anthracyclines and related substance Drugs 0.000 claims description 25
- 210000004881 tumor cell Anatomy 0.000 claims description 22
- -1 cytosine arabinosides Chemical class 0.000 claims description 18
- 238000000034 method Methods 0.000 claims description 16
- 150000001413 amino acids Chemical class 0.000 claims description 13
- 230000003834 intracellular effect Effects 0.000 claims description 13
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 12
- 239000000203 mixture Substances 0.000 claims description 10
- 230000000259 anti-tumor effect Effects 0.000 claims description 9
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 9
- 230000035515 penetration Effects 0.000 claims description 9
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 230000001225 therapeutic effect Effects 0.000 claims description 8
- UHDGCWIWMRVCDJ-CCXZUQQUSA-N Cytarabine Chemical compound O=C1N=C(N)C=CN1[C@H]1[C@@H](O)[C@H](O)[C@@H](CO)O1 UHDGCWIWMRVCDJ-CCXZUQQUSA-N 0.000 claims description 6
- FSBIGDSBMBYOPN-VKHMYHEASA-N L-canavanine Chemical compound OC(=O)[C@@H](N)CCONC(N)=N FSBIGDSBMBYOPN-VKHMYHEASA-N 0.000 claims description 6
- 229940122803 Vinca alkaloid Drugs 0.000 claims description 6
- 238000002360 preparation method Methods 0.000 claims description 6
- 238000003556 assay Methods 0.000 claims description 5
- 229960001156 mitoxantrone Drugs 0.000 claims description 5
- KKZJGLLVHKMTCM-UHFFFAOYSA-N mitoxantrone Chemical compound O=C1C2=C(O)C=CC(O)=C2C(=O)C2=C1C(NCCNCCO)=CC=C2NCCNCCO KKZJGLLVHKMTCM-UHFFFAOYSA-N 0.000 claims description 5
- OIRDTQYFTABQOQ-KQYNXXCUSA-N Adenosine Natural products C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](CO)[C@@H](O)[C@H]1O OIRDTQYFTABQOQ-KQYNXXCUSA-N 0.000 claims description 4
- 239000002126 C01EB10 - Adenosine Substances 0.000 claims description 4
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims description 4
- 229960005305 adenosine Drugs 0.000 claims description 4
- 230000003110 anti-inflammatory effect Effects 0.000 claims description 4
- UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 claims description 4
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims description 4
- GIUYCYHIANZCFB-FJFJXFQQSA-N fludarabine phosphate Chemical compound C1=NC=2C(N)=NC(F)=NC=2N1[C@@H]1O[C@H](COP(O)(O)=O)[C@@H](O)[C@@H]1O GIUYCYHIANZCFB-FJFJXFQQSA-N 0.000 claims description 4
- 150000002224 folic acids Chemical class 0.000 claims description 4
- SGDBTWWWUNNDEQ-LBPRGKRZSA-N melphalan Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N(CCCl)CCCl)C=C1 SGDBTWWWUNNDEQ-LBPRGKRZSA-N 0.000 claims description 4
- UCFGDBYHRUNTLO-QHCPKHFHSA-N topotecan Chemical compound C1=C(O)C(CN(C)C)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 UCFGDBYHRUNTLO-QHCPKHFHSA-N 0.000 claims description 4
- 108010006654 Bleomycin Proteins 0.000 claims description 3
- 241000124008 Mammalia Species 0.000 claims description 3
- 229930192392 Mitomycin Natural products 0.000 claims description 3
- FSBIGDSBMBYOPN-UHFFFAOYSA-N O-guanidino-DL-homoserine Natural products OC(=O)C(N)CCON=C(N)N FSBIGDSBMBYOPN-UHFFFAOYSA-N 0.000 claims description 3
- 229960001561 bleomycin Drugs 0.000 claims description 3
- VSJKWCGYPAHWDS-FQEVSTJZSA-N camptothecin Chemical compound C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-FQEVSTJZSA-N 0.000 claims description 3
- 229940127093 camptothecin Drugs 0.000 claims description 3
- 239000003937 drug carrier Substances 0.000 claims description 3
- 229960005304 fludarabine phosphate Drugs 0.000 claims description 3
- 210000002540 macrophage Anatomy 0.000 claims description 3
- 229960001924 melphalan Drugs 0.000 claims description 3
- 229960004857 mitomycin Drugs 0.000 claims description 3
- 210000001616 monocyte Anatomy 0.000 claims description 3
- TUFFYSFVSYUHPA-UHFFFAOYSA-M rhodamine 123 Chemical compound [Cl-].COC(=O)C1=CC=CC=C1C1=C(C=CC(N)=C2)C2=[O+]C2=C1C=CC(N)=C2 TUFFYSFVSYUHPA-UHFFFAOYSA-M 0.000 claims description 3
- GOLORTLGFDVFDW-UHFFFAOYSA-N 3-(1h-benzimidazol-2-yl)-7-(diethylamino)chromen-2-one Chemical compound C1=CC=C2NC(C3=CC4=CC=C(C=C4OC3=O)N(CC)CC)=NC2=C1 GOLORTLGFDVFDW-UHFFFAOYSA-N 0.000 claims description 2
- SFKZPTYRENGBTJ-UHFFFAOYSA-N 4-methoxynaphthalen-2-amine Chemical compound C1=CC=C2C(OC)=CC(N)=CC2=C1 SFKZPTYRENGBTJ-UHFFFAOYSA-N 0.000 claims description 2
- KLWPJMFMVPTNCC-UHFFFAOYSA-N Camptothecin Natural products CCC1(O)C(=O)OCC2=C1C=C3C4Nc5ccccc5C=C4CN3C2=O KLWPJMFMVPTNCC-UHFFFAOYSA-N 0.000 claims description 2
- 229940000635 beta-alanine Drugs 0.000 claims description 2
- 125000004432 carbon atom Chemical group C* 0.000 claims description 2
- VSJKWCGYPAHWDS-UHFFFAOYSA-N dl-camptothecin Natural products C1=CC=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)C5(O)CC)C4=NC2=C1 VSJKWCGYPAHWDS-UHFFFAOYSA-N 0.000 claims description 2
- JVXXKQIRGQDWOJ-UHFFFAOYSA-N naphthalene-2-carboxamide Chemical compound C1=CC=CC2=CC(C(=O)N)=CC=C21 JVXXKQIRGQDWOJ-UHFFFAOYSA-N 0.000 claims description 2
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 2
- 125000002730 succinyl group Chemical group C(CCC(=O)*)(=O)* 0.000 claims description 2
- 229960000303 topotecan Drugs 0.000 claims description 2
- 125000003440 L-leucyl group Chemical group O=C([*])[C@](N([H])[H])([H])C([H])([H])C(C([H])([H])[H])([H])C([H])([H])[H] 0.000 claims 1
- 229940121363 anti-inflammatory agent Drugs 0.000 claims 1
- 239000002260 anti-inflammatory agent Substances 0.000 claims 1
- 229940104302 cytosine Drugs 0.000 claims 1
- OPTASPLRGRRNAP-UHFFFAOYSA-N cytosine Natural products NC=1C=CNC(=O)N=1 OPTASPLRGRRNAP-UHFFFAOYSA-N 0.000 claims 1
- 230000000149 penetrating effect Effects 0.000 abstract description 2
- 241000699670 Mus sp. Species 0.000 description 31
- 230000035508 accumulation Effects 0.000 description 31
- 238000009825 accumulation Methods 0.000 description 31
- 229960004528 vincristine Drugs 0.000 description 21
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 18
- 230000001413 cellular effect Effects 0.000 description 18
- 235000018102 proteins Nutrition 0.000 description 18
- 102000004169 proteins and genes Human genes 0.000 description 18
- 108090000623 proteins and genes Proteins 0.000 description 18
- 102000035195 Peptidases Human genes 0.000 description 17
- 108091005804 Peptidases Proteins 0.000 description 17
- 238000002347 injection Methods 0.000 description 15
- 239000007924 injection Substances 0.000 description 15
- 239000002207 metabolite Substances 0.000 description 15
- 229940002612 prodrug Drugs 0.000 description 15
- 239000000651 prodrug Substances 0.000 description 15
- 230000001988 toxicity Effects 0.000 description 15
- 231100000419 toxicity Toxicity 0.000 description 15
- 239000003636 conditioned culture medium Substances 0.000 description 14
- 238000011534 incubation Methods 0.000 description 14
- 231100000135 cytotoxicity Toxicity 0.000 description 13
- 230000003013 cytotoxicity Effects 0.000 description 13
- 208000026310 Breast neoplasm Diseases 0.000 description 12
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 12
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 description 12
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 description 12
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 11
- 239000004472 Lysine Substances 0.000 description 11
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 11
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 238000011785 NMRI mouse Methods 0.000 description 10
- 125000003277 amino group Chemical group 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000003328 fibroblastic effect Effects 0.000 description 10
- 235000019833 protease Nutrition 0.000 description 10
- 102000004190 Enzymes Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 9
- 229940024606 amino acid Drugs 0.000 description 9
- 235000001014 amino acid Nutrition 0.000 description 9
- 230000015572 biosynthetic process Effects 0.000 description 9
- DZINNPYMYFDDHL-RCQRPICHSA-N n-[6-[[(1s,3s)-3-acetyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]-2-amino-4-methylpentanamide Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(C)=O)C1CC(NC(=O)C(N)CC(C)C)C(O)C(C)O1 DZINNPYMYFDDHL-RCQRPICHSA-N 0.000 description 9
- 230000007059 acute toxicity Effects 0.000 description 8
- 231100000403 acute toxicity Toxicity 0.000 description 8
- ZYGHJZDHTFUPRJ-UHFFFAOYSA-N coumarin Chemical compound C1=CC=C2OC(=O)C=CC2=C1 ZYGHJZDHTFUPRJ-UHFFFAOYSA-N 0.000 description 8
- 238000007912 intraperitoneal administration Methods 0.000 description 8
- 206010006187 Breast cancer Diseases 0.000 description 7
- 239000004365 Protease Substances 0.000 description 7
- 230000009471 action Effects 0.000 description 7
- 210000002950 fibroblast Anatomy 0.000 description 7
- 238000001727 in vivo Methods 0.000 description 7
- 238000005259 measurement Methods 0.000 description 7
- 239000002609 medium Substances 0.000 description 7
- 238000003786 synthesis reaction Methods 0.000 description 7
- FBOZXECLQNJBKD-ZDUSSCGKSA-N L-methotrexate Chemical compound C=1N=C2N=C(N)N=C(N)C2=NC=1CN(C)C1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 FBOZXECLQNJBKD-ZDUSSCGKSA-N 0.000 description 6
- 231100000111 LD50 Toxicity 0.000 description 6
- 241000699666 Mus <mouse, genus> Species 0.000 description 6
- SJRJJKPEHAURKC-UHFFFAOYSA-N N-Methylmorpholine Chemical compound CN1CCOCC1 SJRJJKPEHAURKC-UHFFFAOYSA-N 0.000 description 6
- 230000015556 catabolic process Effects 0.000 description 6
- 238000006731 degradation reaction Methods 0.000 description 6
- 229940079593 drug Drugs 0.000 description 6
- 238000004128 high performance liquid chromatography Methods 0.000 description 6
- 230000037041 intracellular level Effects 0.000 description 6
- 229960000485 methotrexate Drugs 0.000 description 6
- 241001465754 Metazoa Species 0.000 description 5
- 201000008275 breast carcinoma Diseases 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000002474 experimental method Methods 0.000 description 5
- 230000007062 hydrolysis Effects 0.000 description 5
- 238000006460 hydrolysis reaction Methods 0.000 description 5
- 229960001592 paclitaxel Drugs 0.000 description 5
- 239000000377 silicon dioxide Substances 0.000 description 5
- 230000004580 weight loss Effects 0.000 description 5
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 4
- 229930012538 Paclitaxel Natural products 0.000 description 4
- 230000001154 acute effect Effects 0.000 description 4
- 238000004587 chromatography analysis Methods 0.000 description 4
- 229960000956 coumarin Drugs 0.000 description 4
- 235000001671 coumarin Nutrition 0.000 description 4
- 231100000433 cytotoxic Toxicity 0.000 description 4
- 230000001472 cytotoxic effect Effects 0.000 description 4
- 230000007423 decrease Effects 0.000 description 4
- 238000003745 diagnosis Methods 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- YMZPDIMYPYAWPX-UNTOJKPPSA-N n-[6-[[(1s,3s)-3-acetyl-3,5,10,12-tetrahydroxy-6,11-dioxo-2,4-dihydro-1h-tetracen-1-yl]oxy]-3-hydroxy-2-methyloxan-4-yl]-2-amino-4-methylpentanamide Chemical compound O1C(C)C(O)C(NC(=O)C(N)CC(C)C)CC1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 YMZPDIMYPYAWPX-UNTOJKPPSA-N 0.000 description 4
- 210000004882 non-tumor cell Anatomy 0.000 description 4
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 4
- 235000019419 proteases Nutrition 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 description 4
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical class C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 description 4
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- 206010009944 Colon cancer Diseases 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 239000003153 chemical reaction reagent Substances 0.000 description 3
- 230000000973 chemotherapeutic effect Effects 0.000 description 3
- 238000002512 chemotherapy Methods 0.000 description 3
- 238000001514 detection method Methods 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000000338 in vitro Methods 0.000 description 3
- 231100001231 less toxic Toxicity 0.000 description 3
- 208000032839 leukemia Diseases 0.000 description 3
- 230000010534 mechanism of action Effects 0.000 description 3
- 239000002243 precursor Substances 0.000 description 3
- 102000004196 processed proteins & peptides Human genes 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 239000000243 solution Substances 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- CILBMBUYJCWATM-PYGJLNRPSA-N vinorelbine ditartrate Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O.OC(=O)[C@H](O)[C@@H](O)C(O)=O.C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC CILBMBUYJCWATM-PYGJLNRPSA-N 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- HJEZFVLKJYFNQW-PRFXOSGESA-N (13S)-13-dihydrodaunorubicin Chemical group O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)[C@H](C)O)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 HJEZFVLKJYFNQW-PRFXOSGESA-N 0.000 description 2
- 125000003088 (fluoren-9-ylmethoxy)carbonyl group Chemical group 0.000 description 2
- YOETUEMZNOLGDB-UHFFFAOYSA-N 2-methylpropyl carbonochloridate Chemical compound CC(C)COC(Cl)=O YOETUEMZNOLGDB-UHFFFAOYSA-N 0.000 description 2
- NDMPLJNOPCLANR-UHFFFAOYSA-N 3,4-dihydroxy-15-(4-hydroxy-18-methoxycarbonyl-5,18-seco-ibogamin-18-yl)-16-methoxy-1-methyl-6,7-didehydro-aspidospermidine-3-carboxylic acid methyl ester Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 NDMPLJNOPCLANR-UHFFFAOYSA-N 0.000 description 2
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 2
- HJEZFVLKJYFNQW-UHFFFAOYSA-N Daunorubicinol Natural products C1=2C(O)=C3C(=O)C=4C(OC)=CC=CC=4C(=O)C3=C(O)C=2CC(O)(C(C)O)CC1OC1CC(N)C(O)C(C)O1 HJEZFVLKJYFNQW-UHFFFAOYSA-N 0.000 description 2
- OWCHPBVMSHIYCQ-UHFFFAOYSA-N Dihydro-dauno-mycinon Natural products C1C(O)(C(C)O)CC(O)C2=C1C(O)=C1C(=O)C(C=CC=C3OC)=C3C(=O)C1=C2O OWCHPBVMSHIYCQ-UHFFFAOYSA-N 0.000 description 2
- 102000004157 Hydrolases Human genes 0.000 description 2
- 108090000604 Hydrolases Proteins 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 2
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 description 2
- 239000002253 acid Substances 0.000 description 2
- 150000003797 alkaloid derivatives Chemical class 0.000 description 2
- 239000002246 antineoplastic agent Substances 0.000 description 2
- 231100000259 cardiotoxicity Toxicity 0.000 description 2
- 230000007681 cardiovascular toxicity Effects 0.000 description 2
- 125000003636 chemical group Chemical group 0.000 description 2
- 230000001143 conditioned effect Effects 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 229950000950 daunorubicinol Drugs 0.000 description 2
- 238000010511 deprotection reaction Methods 0.000 description 2
- HPNMFZURTQLUMO-UHFFFAOYSA-N diethylamine Chemical compound CCNCC HPNMFZURTQLUMO-UHFFFAOYSA-N 0.000 description 2
- 230000007071 enzymatic hydrolysis Effects 0.000 description 2
- 238000006047 enzymatic hydrolysis reaction Methods 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000011521 glass Substances 0.000 description 2
- 230000003301 hydrolyzing effect Effects 0.000 description 2
- 238000001990 intravenous administration Methods 0.000 description 2
- 238000010253 intravenous injection Methods 0.000 description 2
- 229960003136 leucine Drugs 0.000 description 2
- YIQATJBOCJPFCF-XQLDGQACSA-N methyl (1R,9R,10S,11R,12R,19R)-12-ethyl-4-[(13S,15R,17S)-17-ethyl-17-hydroxy-13-methoxycarbonyl-1,11-diazatetracyclo[13.3.1.04,12.05,10]nonadeca-4(12),5,7,9-tetraen-13-yl]-8-formyl-10,11-dihydroxy-5-methoxy-8,16-diazapentacyclo[10.6.1.01,9.02,7.016,19]nonadeca-2,4,6,13-tetraene-10-carboxylate Chemical compound CC[C@]1(O)C[C@@H]2CN(C1)CCc1c([nH]c3ccccc13)[C@@](C2)(C(=O)OC)c1cc2c(cc1OC)N(C=O)[C@@H]1[C@]22CCN3CC=C[C@](CC)([C@@H]23)[C@@H](O)[C@]1(O)C(=O)OC YIQATJBOCJPFCF-XQLDGQACSA-N 0.000 description 2
- 229940086322 navelbine Drugs 0.000 description 2
- 239000003208 petroleum Substances 0.000 description 2
- 230000035755 proliferation Effects 0.000 description 2
- 238000011002 quantification Methods 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- 238000010532 solid phase synthesis reaction Methods 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 231100000027 toxicology Toxicity 0.000 description 2
- 230000009466 transformation Effects 0.000 description 2
- 229960003048 vinblastine Drugs 0.000 description 2
- 229960004355 vindesine Drugs 0.000 description 2
- UGGWPQSBPIFKDZ-KOTLKJBCSA-N vindesine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(N)=O)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1N=C1[C]2C=CC=C1 UGGWPQSBPIFKDZ-KOTLKJBCSA-N 0.000 description 2
- NAALWFYYHHJEFQ-ZASNTINBSA-N (2s,5r,6r)-6-[[(2r)-2-[[6-[4-[bis(2-hydroxyethyl)sulfamoyl]phenyl]-2-oxo-1h-pyridine-3-carbonyl]amino]-2-(4-hydroxyphenyl)acetyl]amino]-3,3-dimethyl-7-oxo-4-thia-1-azabicyclo[3.2.0]heptane-2-carboxylic acid Chemical compound N([C@@H](C(=O)N[C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C=1C=CC(O)=CC=1)C(=O)C(C(N1)=O)=CC=C1C1=CC=C(S(=O)(=O)N(CCO)CCO)C=C1 NAALWFYYHHJEFQ-ZASNTINBSA-N 0.000 description 1
- XVXGYZFARCOVHS-BINOZUKVSA-N (7s,9s)-7-[(2r,4s,5s,6s)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-8,10-dihydro-7h-tetracene-5,12-dione Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(=O)CO)C1 XVXGYZFARCOVHS-BINOZUKVSA-N 0.000 description 1
- YEDUAINPPJYDJZ-UHFFFAOYSA-N 2-hydroxybenzothiazole Chemical compound C1=CC=C2SC(O)=NC2=C1 YEDUAINPPJYDJZ-UHFFFAOYSA-N 0.000 description 1
- AOJJSUZBOXZQNB-VTZDEGQISA-N 4'-epidoxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-VTZDEGQISA-N 0.000 description 1
- TVZGACDUOSZQKY-LBPRGKRZSA-N 4-aminofolic acid Chemical compound C1=NC2=NC(N)=NC(N)=C2N=C1CNC1=CC=C(C(=O)N[C@@H](CCC(O)=O)C(O)=O)C=C1 TVZGACDUOSZQKY-LBPRGKRZSA-N 0.000 description 1
- FUXVKZWTXQUGMW-FQEVSTJZSA-N 9-Aminocamptothecin Chemical compound C1=CC(N)=C2C=C(CN3C4=CC5=C(C3=O)COC(=O)[C@]5(O)CC)C4=NC2=C1 FUXVKZWTXQUGMW-FQEVSTJZSA-N 0.000 description 1
- 0 CCCC=C(*)[C@@](C)(C(CC(*)(CC1OC(CO)C#N)O)C1=C(C1=C)O)C1=O Chemical compound CCCC=C(*)[C@@](C)(C(CC(*)(CC1OC(CO)C#N)O)C1=C(C1=C)O)C1=O 0.000 description 1
- 206010048610 Cardiotoxicity Diseases 0.000 description 1
- 102000005600 Cathepsins Human genes 0.000 description 1
- 108010084457 Cathepsins Proteins 0.000 description 1
- 241000557626 Corvus corax Species 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 1
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 102000005593 Endopeptidases Human genes 0.000 description 1
- 108010059378 Endopeptidases Proteins 0.000 description 1
- 206010020919 Hypervolaemia Diseases 0.000 description 1
- XDXDZDZNSLXDNA-TZNDIEGXSA-N Idarubicin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XDXDZDZNSLXDNA-TZNDIEGXSA-N 0.000 description 1
- XDXDZDZNSLXDNA-UHFFFAOYSA-N Idarubicin Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=CC=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XDXDZDZNSLXDNA-UHFFFAOYSA-N 0.000 description 1
- 108060003951 Immunoglobulin Proteins 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- 239000004395 L-leucine Substances 0.000 description 1
- 235000019454 L-leucine Nutrition 0.000 description 1
- 102000005741 Metalloproteases Human genes 0.000 description 1
- 108010006035 Metalloproteases Proteins 0.000 description 1
- 108090000854 Oxidoreductases Proteins 0.000 description 1
- 102000004316 Oxidoreductases Human genes 0.000 description 1
- 108010057150 Peplomycin Proteins 0.000 description 1
- KMSKQZKKOZQFFG-HSUXVGOQSA-N Pirarubicin Chemical compound O([C@H]1[C@@H](N)C[C@@H](O[C@H]1C)O[C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1CCCCO1 KMSKQZKKOZQFFG-HSUXVGOQSA-N 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 108091007187 Reductases Proteins 0.000 description 1
- 229930003268 Vitamin C Natural products 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 229960003896 aminopterin Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000007234 antiinflammatory process Effects 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 230000000721 bacterilogical effect Effects 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 230000029918 bioluminescence Effects 0.000 description 1
- 238000005415 bioluminescence Methods 0.000 description 1
- 230000000903 blocking effect Effects 0.000 description 1
- 210000000481 breast Anatomy 0.000 description 1
- XREUEWVEMYWFFA-CSKJXFQVSA-N carminomycin Chemical compound C1[C@H](N)[C@H](O)[C@H](C)O[C@H]1O[C@@H]1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2C[C@@](O)(C(C)=O)C1 XREUEWVEMYWFFA-CSKJXFQVSA-N 0.000 description 1
- 229930188550 carminomycin Natural products 0.000 description 1
- XREUEWVEMYWFFA-UHFFFAOYSA-N carminomycin I Natural products C1C(N)C(O)C(C)OC1OC1C2=C(O)C(C(=O)C3=C(O)C=CC=C3C3=O)=C3C(O)=C2CC(O)(C(C)=O)C1 XREUEWVEMYWFFA-UHFFFAOYSA-N 0.000 description 1
- 229950001725 carubicin Drugs 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000002738 chelating agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 229910001429 cobalt ion Inorganic materials 0.000 description 1
- XLJKHNWPARRRJB-UHFFFAOYSA-N cobalt(2+) Chemical compound [Co+2] XLJKHNWPARRRJB-UHFFFAOYSA-N 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 239000007822 coupling agent Substances 0.000 description 1
- 229940097362 cyclodextrins Drugs 0.000 description 1
- 229960003109 daunorubicin hydrochloride Drugs 0.000 description 1
- 238000006193 diazotization reaction Methods 0.000 description 1
- 230000029087 digestion Effects 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- MOTZDAYCYVMXPC-UHFFFAOYSA-N dodecyl hydrogen sulfate Chemical compound CCCCCCCCCCCCOS(O)(=O)=O MOTZDAYCYVMXPC-UHFFFAOYSA-N 0.000 description 1
- 229940043264 dodecyl sulfate Drugs 0.000 description 1
- 238000009510 drug design Methods 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000012202 endocytosis Effects 0.000 description 1
- 230000002255 enzymatic effect Effects 0.000 description 1
- ITSGNOIFAJAQHJ-BMFNZSJVSA-N esorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)C[C@H](C)O1 ITSGNOIFAJAQHJ-BMFNZSJVSA-N 0.000 description 1
- 229950002017 esorubicin Drugs 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 230000001747 exhibiting effect Effects 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 150000004676 glycans Chemical class 0.000 description 1
- 231100000086 high toxicity Toxicity 0.000 description 1
- NPZTUJOABDZTLV-UHFFFAOYSA-N hydroxybenzotriazole Substances O=C1C=CC=C2NNN=C12 NPZTUJOABDZTLV-UHFFFAOYSA-N 0.000 description 1
- 229960000908 idarubicin Drugs 0.000 description 1
- 102000018358 immunoglobulin Human genes 0.000 description 1
- 229940072221 immunoglobulins Drugs 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002427 irreversible effect Effects 0.000 description 1
- 150000002576 ketones Chemical group 0.000 description 1
- 231100000187 late toxicity Toxicity 0.000 description 1
- 231100000636 lethal dose Toxicity 0.000 description 1
- 231100000225 lethality Toxicity 0.000 description 1
- KYYQSAMPTLGNIQ-CIGKBZFWSA-N liblomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN(C)CCCN(CC=1C=C(OCC=2C=CC=CC=2)C(OCC=2C=CC=CC=2)=CC=1)CC=1C=C(OCC=2C=CC=CC=2)C(OCC=2C=CC=CC=2)=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C KYYQSAMPTLGNIQ-CIGKBZFWSA-N 0.000 description 1
- 108700020781 liblomycin Proteins 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 208000020816 lung neoplasm Diseases 0.000 description 1
- 229920002521 macromolecule Polymers 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000012423 maintenance Methods 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000000663 muscle cell Anatomy 0.000 description 1
- 230000000926 neurological effect Effects 0.000 description 1
- 230000007135 neurotoxicity Effects 0.000 description 1
- 231100000228 neurotoxicity Toxicity 0.000 description 1
- 150000002895 organic esters Chemical class 0.000 description 1
- 210000001672 ovary Anatomy 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- QIMGFXOHTOXMQP-GFAGFCTOSA-N peplomycin Chemical compound N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCCN[C@@H](C)C=1C=CC=CC=1)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1NC=NC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C QIMGFXOHTOXMQP-GFAGFCTOSA-N 0.000 description 1
- 229950003180 peplomycin Drugs 0.000 description 1
- 210000004303 peritoneum Anatomy 0.000 description 1
- 239000008063 pharmaceutical solvent Substances 0.000 description 1
- 229960001221 pirarubicin Drugs 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 238000004451 qualitative analysis Methods 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 231100000161 signs of toxicity Toxicity 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000008279 sol Substances 0.000 description 1
- 239000008247 solid mixture Substances 0.000 description 1
- 239000007790 solid phase Substances 0.000 description 1
- 238000002798 spectrophotometry method Methods 0.000 description 1
- 239000008174 sterile solution Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 239000003206 sterilizing agent Substances 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 150000003573 thiols Chemical class 0.000 description 1
- 210000001519 tissue Anatomy 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- GBABOYUKABKIAF-IELIFDKJSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-IELIFDKJSA-N 0.000 description 1
- 239000011718 vitamin C Substances 0.000 description 1
- 235000019154 vitamin C Nutrition 0.000 description 1
- 239000003643 water by type Substances 0.000 description 1
- 230000004584 weight gain Effects 0.000 description 1
- 235000019786 weight gain Nutrition 0.000 description 1
- 238000009736 wetting Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K9/00—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof
- C07K9/001—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure
- C07K9/005—Peptides having up to 20 amino acids, containing saccharide radicals and having a fully defined sequence; Derivatives thereof the peptide sequence having less than 12 amino acids and not being part of a ring structure containing within the molecule the substructure with m, n > 0 and m+n > 0, A, B, D, E being heteroatoms; X being a bond or a chain, e.g. muramylpeptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/65—Peptidic linkers, binders or spacers, e.g. peptidic enzyme-labile linkers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/0019—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules
- A61K49/0021—Fluorescence in vivo characterised by the fluorescent group, e.g. oligomeric, polymeric or dendritic molecules the fluorescent group being a small organic molecule
- A61K49/0041—Xanthene dyes, used in vivo, e.g. administered to a mice, e.g. rhodamines, rose Bengal
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0052—Small organic molecules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/001—Preparation for luminescence or biological staining
- A61K49/0013—Luminescence
- A61K49/0017—Fluorescence in vivo
- A61K49/005—Fluorescence in vivo characterised by the carrier molecule carrying the fluorescent agent
- A61K49/0056—Peptides, proteins, polyamino acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Definitions
- the present invention relates to new compounds, the pharmaceutical composition and the diagnostic device comprising them and the use thereof for the preparation of medicaments intended for the treatment and / or for the diagnosis of cancerous tumors and / or inflammatory reactions.
- tumor agents such as anthracyclines and vinca alkaloids
- anthracyclines and vinca alkaloids have been developed in recent years and are particularly effective for the treatment of cancers.
- these molecules are often characterized in vivo by acute toxicity, in particular spinal and mucosal toxicity as well as chronic cardiac toxicity in anthracyclines and neurological in vinca alkaloids.
- Patent US-4,296,105 describes doxorubicin derivatives linked to an amino acid, optionally substituted, which have in vitro a higher anti-tumor activity and a lower toxicity than doxorubicin.
- Prodrugs are molecules that can transform into drugs (active therapeutic compounds) by certain chemical or enzymatic changes in their structure.
- prodrugs are also characterized by poor stability in blood and serum, which contain enzymes which inactivate these molecules.
- prodrugs comprising a vector linked by a peptide arm to the drug.
- the arm consists of four amino acids and is linked by its free carboxylic function to the free amino function of anthracycline derivatives such as daunorubicin.
- the arm of these prodrugs is linked by its free amino function to a vector consisting of a macromolecule (protein such as BSA, immunoglobulins, etc.) which allows the selective endocytosis of the prodrug by target cells. .
- a macromolecule protein such as BSA, immunoglobulins, etc.
- methotrexate can be used for the treatment of inflammatory reactions such as rheumatism, but its high toxicity limits its applications.
- the present invention aims to provide new compounds comprising an anti-tumor therapeutic agent or a marker, in particular prodrugs comprising an anti-tumor therapeutic agent, exhibiting improved therapeutic properties compared with the state of the art products, in particular therapeutic properties. improved in the treatment of cancerous tumors and / or in the treatment of inflammatory reactions such as rheumatism.
- a particular object of the present invention is to obtain prodrugs which have a high specificity of action, reduced toxicity and improved stability in serum and blood.
- An additional aim of the present invention is to obtain compounds comprising a marker making it possible to characterize tumors (diagnosis, evolution of the tumor, assay of the factors secreted by the tumor cells, etc.).
- the present invention relates to compounds (WZM) comprising an element chosen from the group consisting of markers and therapeutic agents, preferably antitumor and / or anti-inflammatory, having an active intracellular site (SA), linked to a ligand (WZ ) comprising an arm (Z) linked to a terminal group (W) in which the connection between the arm (Z) of the ligand (WZ) and the element (M) prevents cellular penetration of the compound (WZM) and / or inhibits expression of the marker (M); in which this bond is selectively cleavable by factors secreted by target cells, so as to allow expression of the marker (M) and / or penetration of the therapeutic agent (M) in said target cells, and in which the terminal group (W) ensures the stability of the compound (WZM) in the serum and in the circulating blood.
- the term factors secreted by target cells in particular by tumor cells and cells involved in inflammatory reactions (macrophages, monocytes, etc.), enzymes such as proteases or
- These enzymes are therefore capable of selectively cleaving the bond existing between the element (M) and the arm (Z) of the ligand (W-Z) so as to allow expression of the marker; advantageously in the environment of said cells and / or the penetration of the therapeutic agent, preferably in said cells, and in this way ensuring their destruction and / or blocking their proliferation.
- the bond between the terminal group (W) and the arm (Z) as well as the bond between the arm (Z) and the element (M) can be any type of covalent bond, not affecting the properties of the compound (WZM ) according to the invention.
- bond between the arm (Z) of the ligand (W-Z) and the marker (M) inhibiting the expression of the marker (M) means any covalent bond preventing the detection and / or quantification of the marker (M).
- the expression of the free marker (M) can be detected by any process or device well known to those skilled in the art, for example by detection by coloring, fluorescence, bioluminescence, chemoluminescence, possibly involving one or more intermediate reagents.
- said marker is chosen from the group consisting of coumarin, 7-amido-4-trifluoromethyl coumarin, paranitroanilide (which can be characterized in its free form by colorimetry after diazotization reaction), ⁇ -naphthylamide and 4-methoxy- ⁇ -naphthylamide, and is capable of being detected by fluorescence when it is no longer linked to the ligand (WZ).
- terminal group (W) ensuring the stability of the compound according to the invention in the serum and in the circulating blood, any group which reduces or inhibits the cleavage of the compound according to the invention in the serum and the circulating blood, in particular which reduces or inhibits the hydrolysis of the compound according to the invention by proteinases and peptidases present in serum and / or circulating blood, in particular the peptidases and proteinases associated with red blood cells.
- a terminal group (W) ensures the stability of the compound according to the invention when less than 20%, preferably less than 2%, of the compound is cleaved by said enzymes during its conservation in human blood at 37 ° C for more than 2 hours.
- this terminal group (W) is chosen from the group consisting of amino acids not present in mammals (that is to say amino acids not genetically encodable by mammals) or a succinyl group.
- the group (W) is ⁇ -Alanine of formula: NH 2 - CH 2 - CH 2 - COOH, linked by its carboxylic function to the arm (Z).
- the arm (Z) can be made up of any chemical structure (polysaccharides, peptides, etc.) the binding of which to element (M) is capable of being selectively cleaved by the factors secreted by the target cells so as to allow the expression of the marker (M) in the environment of said cells and / or the penetration of the therapeutic agent (M) preferentially in said cells.
- the link between the element (M) and the arm (Z) of the ligand (W-Z) consists of a peptide link.
- the arm (Z) is a peptide consisting of at least two optionally substituted amino acids.
- the ligand arm (Z) (WZ) consists of preferably by the succession of the following amino acids: L-Leucyl-L-Alanyl-L-Leucyl, L-Leucyl-L-Alanyl or L-Alanyl-L- Leucyl-L-Phenylalanyl or L-Alanyl-L-Leucyl, linked by their carboxylic function at element (M).
- the therapeutic agent (M) is either a therapeutic agent used in cancer chemotherapy, preferably chosen from the therapeutic agents described by Bruce A. Chabner and Jerry M. Collins (Cancer Chemotherapy, Lippincott Ed., ISBN 0-397-50900-6 (1990)), or an anti-inflammatory such as methotrexate; and capable of binding to the ligand (W-Z), preferably by a peptide link to the group (Z) of the ligand (W-Z).
- the therapeutic agent is chosen from the group consisting of anthracyclines, folic acid derivatives, vinca alkaloids, mitoxanthrone, calichéamycin, cytosine arabinoside (ARA-C), adenosine arabinoside (ARA- A), fludarabine phosphate, melphalan, bleomycin, mitomycin, L-canavanine, taxoids, camptothecin and their derivatives, in particular TOPOTECAN ® (9-dimethylaminomethyl-10-hydroxy camptothecin hydrochloride), derivatives fluorochromes, such as rhodamine 123 and its derivatives, in particular rhodamine isothiocyanates, optionally linked to a substituted or unsubstituted amino acid.
- the substitution on the amino acid can be any substitution which does not affect the properties of the compound (W-Z-M) according to the invention.
- derivatives of these molecules means said molecules modified by a chemical group allowing their attachment to the arm (Z) of the ligand (W-Z) by a covalent link which does not affect the therapeutic activity of the original molecule.
- the therapeutic agent (M) is chosen from the group of anthracyclines, in particular doxorubicin (DOX) and daunorubicin (DNR), optionally linked to a substituted or unsubstituted amino acid.
- DOX doxorubicin
- DNR daunorubicin
- the therapeutic agent corresponds to the general formula:
- R 1 is a hydrogen atom or an OH group
- R 2 is a hydrogen atom or a radical of formula in which :
- R 3 is a hydrogen atom or an alkyl radical, optionally substituted
- R 4 represents a hydrogen atom or forms with R 3 an alkylene radical containing 3 or 4 carbon atoms.
- R 2 is a radical of formula:
- the compound is ⁇ Alanyl-L-Leucyl-L-Alanyl-L- Leucyl-daunorubicin (identified by ⁇ Ala-Leu-Ala-Leu-DNR everywhere below), the ⁇ Alanyl-L-Leucyl-L-Alanyl-L-Leucyl- doxorubicin (identified by ⁇ Ala-Leu-Ala-Leu-DOX everywhere below), ⁇ Alanyl-L-Alanyl-L-Leucyl-L-Phenylalanyl- daunorubicin (identified by ⁇ Ala-Ala-Leu-Phe-DNR everywhere below) or ⁇ Alanyl-L-Alanyl-L-Leucyl-L-Phenylalanyl- doxorubicin (identified by ⁇ Ala-Ala-Leu-Phe-DOX everywhere below
- the present invention also relates to the pharmaceutical composition
- the pharmaceutical composition comprising the compound according to the invention and optionally an acceptable pharmaceutical adjuvant or vehicle.
- compositions can for example be administered parenterally or intravenously.
- the compositions according to the invention for parenteral administration can be in particular aqueous or non-aqueous sterile solutions, suspensions or emulsions.
- an acceptable pharmaceutical solvent or vehicle propylene glycol, polyethylene glycol, injectable organic esters, for example ethyl oleate, or cyclodextrins can be used.
- These compositions can also comprise wetting, emulsifying and / or dispersing agents.
- Sterilization can be done in several ways, for example using a bacteriological filter by incorporating sterilizing agents into the composition, or by irradiation. They can also be prepared in the form of sterile solid compositions, which can be dissolved at the time of use in sterile water or any other sterile injectable medium.
- the present invention may also include adjuvants well known to those skilled in the art (vitamin C, antioxidant agents, etc.) which can be used in synergy with the compound according to the invention to improve and prolong the treatment of cancerous tumors.
- adjuvants well known to those skilled in the art vitamin C, antioxidant agents, etc.
- the minimum doses for administering the compounds according to the invention to a patient are the usual doses of the abovementioned anti-tumor therapeutic agents, as described in particular by Bruce A. Chabner and Jerry M. Collins (Cancer Chemotherapy, Lippincott Ed., ISBN 0 -397- 50900-6 (1990)) or higher dosages.
- the doses administered therefore vary depending on the therapeutic agent used for the preparation of the compound according to the invention.
- the present invention relates to the use of the pharmaceutical composition according to the invention for the preparation of a medicament intended for the treatment of cancerous tumors, as well as to a method of therapeutic treatment of cancerous tumors, consisting in the administration, in particular by parenterally or intravenously, to a patient of the pharmaceutical composition according to the invention.
- the present invention also relates to the use of the pharmaceutical composition according to the invention for the preparation of a medicament intended for the treatment of inflammatory reactions, in particular rheumatism, as well as a method of therapeutic treatment of inflammatory reactions, in particular of rheumatism, consisting in the administration, in particular parenterally or intravenously, to a patient of the pharmaceutical composition according to the invention, in particular, a pharmaceutical composition comprising a compound according to the invention in which the therapeutic agent (M) is methotrexate or a methotrexate derivative.
- M therapeutic agent
- Another aspect of the present invention relates to a diagnostic and / or assay device comprising the compound according to the invention, in particular the compound comprising, as a marker, coumarin.
- FIG. 1 represents the mechanism of action of the compound according to the invention on its site of action (S.A.) in a target cell (C.C.).
- FIG. 2 represents the mechanism of action of the compound according to the invention in a normal cell (CN).
- FIG. 3 represents the hydrolysis of ⁇ -Ala-Leu-Ala-
- FIG. 4 represents the hydrolysis of ⁇ -Ala-Leu-Ala- Leu-daunorubicin in conditioned medium of MCF7 / ADR human mammary carcinoma cells (chromatogram at initial time (a) and after one hour of incubation (b )).
- FIG. 5 represents the hydrolysis of ⁇ -Ala-Leu-Ala-
- FIG. 6 shows the accumulation of daunorubicin
- FIG. 7 represents the accumulation of N-L-Leucyl-daunorubicin (Leu-DNR) at the concentration of
- FIG. 8 represents the accumulation of ⁇ -Ala-Leu-Ala-
- FIG. 9 shows the accumulation of daunorubicin
- FIG. 10 represents the accumulation of NL-Leucyldununorubicin (Leu-DNR) at the concentration of 10 ⁇ g eq. DNR / ml by confluent MRC5 fibroblastic cells.
- Figure 11 represents the accumulation of ⁇ -Ala-Leu-Ala-
- Figure 12 shows the cytotoxicity of daunorubicin
- Figure 13 shows the cytotoxicity of daunorubicin
- Figure 14 shows the mortality of female NMRI mice after i.p. 5 consecutive days of daunorubicin (DNR) at total doses between 2.0 and 3.5 mg / kg.
- DNR daunorubicin
- FIG. 15 represents the evolution of the average weight of the female NMRI mice having received i.p. 5 consecutive days of total doses of daunorubicin between 2.0 and 3.5 mg / kg. Weights are expressed as a percentage of the average initial weight for each group.
- FIG. 16 represents the mortality of female NMRI mice after i.p. administration. 5 consecutive days of ⁇ -Ala-Leu-Ala-Leudaunorubicin at total doses between 10 and 60 mg / kg.
- FIG. 17 represents the evolution of the average weight of the female NMRI mice having received i.p. 5 consecutive days of total doses of ⁇ - Ala-Leu-Ala-Leu-daunorubicin between
- Weights are expressed in percentage of the average initial weight for each group.
- FIG. 18 represents the mortality of female NMRI mice after a single i.v. administration of daunorubicin (DNR) at doses between 10 and 35 mg / kg.
- DNR daunorubicin
- FIG. 19 represents the evolution of the average weight of female NMRI mice having received i.v. doses of daunorubicin (DNR) of between 10 and 35 mg / kg. Weights are expressed as a percentage of the average initial weight for each group.
- DNR daunorubicin
- FIG. 20 represents the change in the average weight of female NMRI mice having received i.v. doses of ⁇ -Ala-Leu-Ala-Leu-daunorubicin of 30 and 60 mg / kg. Weights are expressed as a percentage of the average initial weight for each group.
- FIG. 21 represents the evolution of the average weight of the female NMRI mice having received by the iv route either a dose of 30 mg / kg of ⁇ -Ala-Leu-Ala- Leu-daunorubicin, or two doses of 30 mg / kg each two consecutive days. Weights are expressed as a percentage of the average initial weight for each group.
- FIG. 22 represents the kinetics of enzymatic hydrolysis of ⁇ -Ala-Leu-Ala-Leu-doxorubicin into L-Ala-L-Leu-doxorubicin and L-
- Leu-doxorubicin in a medium conditioned by MCF7 / 6 cells Leu-doxorubicin in a medium conditioned by MCF7 / 6 cells.
- Figure 23 shows the accumulation of doxorubicin
- FIG. 24 represents the accumulation of L-Leudoxorubicin at the concentration of 10 ⁇ g / ml by confluent MCF7 / 6 cells.
- Figure 25 shows the accumulation of ⁇ -Ala-Leu-Ala-
- Figure 26 shows the accumulation of doxorubicin
- FIG. 27 represents the accumulation of L-Leudoxorubicin at the concentration of 10 ⁇ g / ml by confluent MRC5 fibroblastic cells.
- Figure 28 represents the accumulation of ⁇ -Ala-Leu-Ala-
- Figure 29 shows the cytotoxicity of doxorubicin
- Ala-Leu-Ala-Leu-doxorubicin vis-à-vis the MCF7 / 6 cells maintained in growth for 72 hours in the presence of said anthracycline derivatives.
- Figure 30 shows the cytotoxicity of doxorubicin
- Ala-Leu-Ala-Leu-doxorubicin vis-à-vis the fibroblastic cells MRC5 maintained in growth for 72 hours in the presence of said anthracycline derivatives.
- FIG. 31 represents the variation of the average tumor mass of a human mammary tumor MCF7 / 6 implanted in athymic mice on day T-21 as a function of the administration of doxorubicin (DOX) and of ⁇ -Ala-Leu-Ala -Leu- doxorubicin (super DOX).
- DOX doxorubicin
- super DOX ⁇ -Ala-Leu-Ala -Leu- doxorubicin
- FIG. 32 represents the variation in the average weight of mice (grams) treated with the administration of doxorubicin (DOX) and of ⁇ -Ala-Leu-Ala-Leu-doxorubicin (super DOX).
- FIG. 33 represents the expression of the free coumarin marker (number of moles of coumarin released per milligram of cellular proteins) in test tubes comprising the compound according to the invention with homogenates of tumor cells, homogenates of transformed cells and normal cell homogenates.
- the present invention is based on the unexpected discovery that it is possible to make a marker or a therapeutic agent (M), in particular an anti-tumor and / or anti-inflammatory therapeutic agent, inactive by binding with a ligand (WZ) which inhibits expression of the marker or prevents intracellular penetration of the therapeutic agent (M) into normal cells (CN) and target cells (CC).
- M therapeutic agent
- WZ ligand
- said target cells are tumor cells or cells involved in anti-inflammatory reactions, in particular linked to rheumatism, such as macrophages, monocytes, etc.
- the target cells (CC) release in the extracellular medium enzymes such as proteases or peptidases which are capable of selectively hydrolyzing a covalent bond between the arm (Z) of the ligand (WZ) and the marker (M ) or the therapeutic agent (M), so as to allow the expression of the marker (M) or the penetration of the therapeutic agent (M) in said target cells (CC).
- the therapeutic agent (M) acts either directly on its specific intracellular site of action (SA) or after a modification under the action of intracellular proteases, changes to another therapeutic agent (M *) and kills the target cell (CC) or blocks its proliferation ( Figure 1).
- the compound according to the invention is kept inactive and does not enter normal cells ( Figure 2).
- the expression of the marker makes it possible to characterize the cancer cells, thus improving the diagnosis of cancer, the study of the evolution of the tumor, the assay of the factors secreted by tumor cells, ...
- the binding with the ligand (W-Z) prevents intracellular penetration of the therapeutic agent (M) both in normal cells and in target cells.
- the compound according to the invention remains stable in serum and in the blood, and is insensitive to the action of circulating proteinases and peptidases associated with red blood cells.
- the covalent bond existing between the therapeutic agent (M) and the ligand (W-Z) is partially or totally degraded by the enzymes secreted by the target cells.
- the nature of the ligand (WZ) and its binding to the marker or to the therapeutic agent (M) are determined as a function of the enzymes secreted by the target cells. 6.
- the compound is less toxic in vivo than the starting therapeutic agent. This reduction in toxicity relates in particular to acute effects such as spinal and mucosal toxicity, as well as possible cardiac or neurological toxicity.
- the therapeutic agent (M) according to the invention can be an anthracycline derivative, in particular doxorubicin, daunorubicin, 4-epi-doxorubicin, 4-demethoxy-doxorubicin (Idarubicin), 4'-tetrahydropyranyl- doxorubicin (Pirarubicin), carminomycin, esorubicin and 4 '-iodo-doxorubicin.
- doxorubicin doxorubicin, daunorubicin, 4-epi-doxorubicin, 4-demethoxy-doxorubicin (Idarubicin), 4'-tetrahydropyranyl- doxorubicin (Pirarubicin), carminomycin, esorubicin and 4 '-iodo-doxorubicin.
- the ligand (W-Z) is then linked by its carboxylic function to the ⁇ -amino end of the therapeutic agent. Folic acid derivatives.
- the anti-tumor therapeutic agent can also be a derivative of folic acid, in particular methotrexate (MTX) or its derivatives, such as lysine ( ⁇ - ⁇ ) - MTX or lysine ( ⁇ - ⁇ ) -MTX as described by Fitzpatrick et al. (Anti-cancer Drug Design 10, pp. 1-9 and pp. 11-24 (1995)) or aminopterin, in particular lysine ( ⁇ - ⁇ ) -AMPT and lysine ( ⁇ - ⁇ ) -AMPT.
- methotrexate MTX
- its derivatives such as lysine ( ⁇ - ⁇ ) -MTX or lysine ( ⁇ - ⁇ ) -MTX as described by Fitzpatrick et al. (Anti-cancer Drug Design 10, pp. 1-9 and pp. 11-24 (1995)) or aminopterin, in particular lysine ( ⁇ - ⁇ ) -AMPT and lysine ( ⁇ - ⁇ ) -AMPT.
- the ligand (W-Z) is then linked by its carboxylic function to the ⁇ -amino end of the therapeutic agent.
- Vinca alkaloid derivatives Vinca alkaloid derivatives.
- the vinca alkaloid derivatives according to the present invention are in particular derivatives of vinblastine, vincristine, vindesine and navelbine.
- the deacetylvincristine acid can also be obtained by adding an aliphatic diamine to vincristine (NH 2 -alkyl-NH 2 ) so as to obtain an NH 2 -alkyl-dAcVCR, the ligand (WZ) then being linked by its end carboxylic to the ⁇ -amino group of lysine ( ⁇ ) -dAcVCR.
- VBL vinblastine
- navelbine 5'-noranhydrovinblastine
- V 4 -hemiaspartate-vincristine is formed from vincristine by binding of aspartic acid through its ⁇ -carboxylic group to the hydroxyl group in position 4 of vincristine (V 4 ). Then, the ligand (ZW-Z is linked by its carboxylic end to the ⁇ -amino group of V 4 -hemiaspartate-vincristine.
- V 4 -lysyl-vincristine is formed from vincristine by binding lysine through its ⁇ -carboxylic group to the hydroxyl group in position 4 of vincristine (V 4 ). Then, the ligand (WZ) is linked by its carboxylic end to the ⁇ -amino group of V 4 - lysyl-vincristine.
- V 4 -lysyl-vincristine is formed from vincristine by binding lysine by its ⁇ -carboxylic group to the hydroxyl group in position 4 of vincristine (V 4 ). Then, the ligand (WZ) is linked by its carboxylic end to the e-amino group of the lysine of V 4 -lysyl-vincristine. According to an alternative, the ligand (WZ) can be linked to both the ⁇ - and e-amino groups of V 4 -lysyl-vincristine.
- V 4 - ⁇ -Alanyl-vincristine is formed from vincristine by binding ⁇ -Alanyl by its carboxylic group to the hydroxyl group in position 4 of vincristine (V4).
- the ligand (WZ) is linked by its carboxylic end to the amino group of ⁇ -Alanyl of V 4 - ⁇ -Alanyl-vincristine.
- Vinblastine, vindesine and navelbine derivatives can be linked to the ligand (WZ) in the same manner as described above for vincristine.
- N-Acetyl-dimethylhydrazide derived from calichéamycin is obtained by reaction of a thiol hydrazide on calichéamycin.
- the ligand (W-Z) is then linked by its carboxylic end to the N-Acetyl-dimethylhydrazide derived from calichéamycin.
- a mitoxanthrone-derived ⁇ -Alanyl is prepared by linking the carboxylic function of ⁇ -Alanyl to the hydroxyl side chains of the mitoxanthrone.
- ligand W-Z
- W-Z is then linked by its carboxylic end to the amino group of ⁇ -Alanyl-mitoxanthrone.
- Cytosine arabinoside derivatives ARA-C
- the ligand (W-Z) is linked by its carboxylic end to the amino group of the cytosine arabinoside.
- Adenosine arabinoside derivatives (Ara-A).
- the ligand (W-Z) is linked by its carboxylic end to the amino group of adenosine arabinoside. Fludarabine phosphate derivatives.
- the ligand (W-Z) is linked by its carboxylic end to the amino group of fludarabine phosphate.
- the ligand (W-Z) is linked by its carboxylic end to the amino group of melphalan.
- the ligand (WZ) is linked by its carboxylic end to the amino group of bleomycin, peplomycin or liblomycin. Mitomycin derivatives.
- the ligand (W-Z) is linked by its carboxylic end to the amino group in position 7 of mitomycin.
- Derivatives of L-eanavanina are possible.
- the ligand (W-Z) is linked by its carboxylic end to the ⁇ -amino group of L-canavanine.
- a ⁇ -Alanyl derivative of taxol is prepared by linking the carboxylic function of ⁇ -Alanyl to the hydroxyl side chains in position 7 of the taxol.
- hydroxyl group of taxol is reactive but not essential to the antitumor activity of taxol (Nicalaou KC et al., Chemistry and Biology of Taxol, Angew. Chem. Int. Ed. Engl. (1994), 33, pp. 15- 44).
- the ligand (W-Z) is linked by its carboxylic end to the amino group of ⁇ -Alanyl-taxol.
- the ligand (W-Z) can be linked in a comparable manner to the ⁇ -Alanyl-taxoter derivative.
- the ligand (W-Z) is linked by its carboxylic end to the ⁇ -amino group of 9-amino-camptothecin or of 7-amino-methyl-camptothecin.
- L-Leucyl-daunorubicin is synthesized by reaction of daunorubicin in base form (DNR) with L-Leucine protected on its amino function by an FMOC group (fluorenyl-methoxy-carbonyl) and whose carboxylic function is activated by IBCF (isobutylchloroformiate), then deprotection of the amino function.
- the DNR in the base form is prepared from 200 mg of daunorubicin hydrochloride (R. Bellon) dissolved in 500 ⁇ l of DMF (dimethylformamide) to which 1.2 equivalents of N-Methyl-Morpholine are added.
- Fmoc-N-L-Leucyl-daunorubicin is precipitated in 150 ml of a 1: 1 mixture of ether and petroleum ether
- N-L-Leucyl-DNR is precipitated by a 1: 1 mixture of ether and petroleum ether (40-60 ° C), then filtered through sintered glass no4. The product is taken up in a chloroform / methanol mixture (4: 1 by volume) and the diethylamine is neutralized with an equivalent of HCl.
- the product is then purified by chromatography on a silica column (Si-60 silica 70-230 mesh from E. MERCK) eluted with chloroform, then chloroform containing 15% methanol.
- the fractions containing NL-Leucyl-DNR are rotavaped, the product taken up in distilled water and the hydrochloride formed by adjusting the pH to 7 with IN HCl.
- the product is then filtered on modified silica gel (Seppak C18 from WATERS), the hydrochloride of NL-Leucyl-daunorubicin is eluted with methanol and then rotavaped.
- the usual yield is 70 to 80%.
- Tr HPLC retention time with respect to doxorubicin, HPLC system: Si-60 column, eluted with a chloroform: methanol: acetic acid: sol. 0.3 mM aqueous MgCl2 (1440: 420: 80: 60, by volume).
- ⁇ -L-Alanyl-L-Leucyl-L-Alanine is prepared by solid phase synthesis according to the technique of Merrifield (The Chemistry of Polypeptides, (PG Katsoyannis Ed.), Plenum Press, New-York, pp. 336- 361 (1973)).
- the ligand (W-Z) is linked by its carboxylic end to the amino group of rhodamine 123.
- ⁇ -Ala-Leu-Ala-Leu-DNR is synthesized by grafting Fmoc- ⁇ -L-Alanyl-L-Leucyl-L-Alanine, prepared by synthesis in solid phase, onto N-L-Leucyl-daunorubicin.
- ⁇ -Ala-Leu-Ala-Leu-DOX is synthesized by grafting ⁇ -L-Alanyl-L-Leucyl-L-Alanine, prepared by solid phase synthesis, onto NL-Leucyl-doxorubicin, as described for the synthesis of ⁇ -Ala-Leu-Ala-Leu-DNR.
- the coupling agent (isobutyl chloroformate) can be omitted so as to further increase the production yield of the compound according to the invention in the case of the formation of ⁇ -Ala-Leu-Ala-Leu-DOX.
- ⁇ -Ala-Leu-Ala-Leu-DNR was incubated at 37 ° C for 2 hours in conditioned cell medium
- L-Leu-DNR is the major metabolite of endopeptidase and that its formation from the prodrug is almost complete after 1 hour of incubation at 37 ° C. Under the experimental conditions used, the L-Leu-L-Ala-L-Leu-DNR and the DNR are not sufficiently separated so that it can be affirmed with certainty that the L-Leu-DNR formed then hydrolyses more slowly in DNR.
- ⁇ -Ala-Leu-Ala-Leu-DOX is hydrolyzed less rapidly than the prodrug of DNR by the peptidase or peptides secreted by MCF7 / 6 cells.
- the transformation of L-Leu-DOX into DOX seems a little more important than the transformation of L-Leu-DNR into DNR.
- ⁇ -Ala-Leu- Ala-Leu-DOX is stable when incubated at 37 ° C in human blood. Indeed, less than 2% of the prodrug is hydrolyzed in L-Leu-DOX after 2 hours, while the other synthesized derivatives hydrolyze quickly in the presence of human blood (see Table 1 below).
- the MCF7 / 6 cells sensitive and resistant to anthracyclines, both secrete the protease (s) capable of hydrolyzing the compound according to the invention.
- the cells of the human mammary carcinoma MCF7 / 6 were incubated in the presence of ⁇ -Ala-Leu-Ala-Leu-DNR at a concentration of 10 ⁇ g eq. DNR / ml. After various times, the accumulation of prodrugs and their fluorescent metabolites were determined by HPLC after extraction in products at basic pH, according to a method developed in the laboratory. The accumulations, expressed in ⁇ g / mg of cellular proteins, were compared with those of DNR and DOX as well as those of L-Leu-DNR and L-Leu-DOX. The metabolites were identified by determining the retention times of reference products synthesized in the laboratory.
- DNR rapidly accumulates in MCF7 / 6 cells essentially in unchanged form, the maximum accumulation ( ⁇ 15 ⁇ g / mg of cellular proteins) being reached after 6 hours of incubation. The accumulation of DNR then decreases up to 24 hours.
- the main intracellular metabolite is daunorubicinol, resulting from the reduction of the ketone function of DNR, in position Cl3, by intracellular reductases ( Figure 6).
- L-Leu-DNR also accumulates very rapidly by MCF7 / 6 cells, but at lower rates and the accumulation reaches a plateau after 24 hours of incubation, being ⁇ 14 ⁇ g / mg of cellular proteins. DNR is formed intracellularly over time to reach 14% of total intracellular fluorescence after 24 hours of incubation (Figure 7).
- ⁇ -Ala-Leu-Ala-Leu-DNR incubated for 24 hours in the presence of MCF7 / 6 cells, accumulates in unchanged form, much less than DNR and that L-Leu-DNR, the accumulation rate being only ⁇ 1 ⁇ g / mg of cellular proteins ( Figure 8).
- Figure 8 These are essentially L-Leu-DNR, formed extracellularly, and DNR that are found in cells after 24 hours of incubation. The DNR found intracellularly represents, after 24 hours of incubation, approximately 40% of the total fluorescence.
- the MRC5 fibroblast cells were incubated in the presence of ⁇ -Ala-Leu-Ala-Leu-DNR at a concentration of 10 ⁇ g eq. DNR / ml.
- the accumulation of prodrugs and their fluorescent metabolites was determined by HPLC after extraction of the products at pH basic, according to a method developed in the laboratory.
- the accumulations, expressed in ⁇ g / mg of cellular proteins, were compared with those of DNR and L-Leu-DNR.
- the metabolites were identified by determining the retention times of reference products synthesized in the laboratory.
- DNR mainly accumulates in MRC5 cells in unchanged form, and the accumulation reaches a plateau of ⁇ 76 ⁇ g / mg of cellular proteins after 6 hours, the major metabolite being daunorubicinol (Figure 9).
- L-Leu-DNR also accumulates very quickly by MRC5 cells, but at lower rates, and the accumulation reaches a plateau after 24 hours of incubation, being ⁇ 40 ⁇ g / mg of cellular proteins.
- the main metabolites are DNR as well as L-Leu-DNR-OL ( Figure 10).
- ⁇ -Ala-Leu-Ala-Leu-DNR incubated for 24 hours in the presence of MRC5 cells, accumulates much less than DNR and L-Leu-DNR, the accumulation rate being only ⁇ 3.3 ⁇ g / mg of cellular proteins ( Figure 11). It is essentially L-Leu-DNR, formed extracellularly, that is found in cells. Its accumulation increases linearly up to 24 hours of incubation.
- the intracellular levels obtained of DNR after 24 hours of incubation in the presence of the compound ⁇ -Ala-Leu-Ala-Leu-DNR are 12 times higher than in MRC5 fibroblasts.
- the cytotoxicity of the prodrug DNR, Leu-DNR and DNR was compared on MCF7 / 6 and MRC5 cells maintained in growth for 72 hours in the presence of the various compounds.
- the cytotoxicities of ⁇ -Ala-Leu-Ala-Leu-DNR, L-Leu-DNR and DNR were determined on MCF7 / 6 cells growing in 96-well dishes, incubated in the presence of increasing concentrations. of various compounds. After 72 hours, the cells are incubated for 48 hours in the absence of anthracycline and the cytotoxicity is determined by measurement of the cellular proteins by the Bradford technique. A range of 9 concentrations are used. ranging from 700 ⁇ g / ml to 0.0035 ⁇ g / ml, and each measurement represents an average and a standard deviation of 6 values. The experimental points are adjusted to a sigmoid curve which makes it possible to calculate the inflection point corresponding to the dose at which half of the cells survive (IC 50 ).
- Figure 12 illustrates that the IC 50 of the DNR is 0.090 ⁇ 0.004 ⁇ g / ml.
- the IC 50 is 1.30 ⁇ 0.56 ⁇ g / ml.
- the IC 50 is 22.00 ⁇ 7.31 ⁇ g / ml
- Leu-DNR and ⁇ -Ala-Leu-Ala-Leu-DNR are therefore respectively 14 times and 244 times less cytotoxic than DNR for cells of human mammary carcinoma MCF7 / 6 maintained in growth for 72 hours in the presence of anthracyclines .
- the cytotoxicity of ⁇ -Ala-Leu-Ala-Leu-DNR, L-Leu-DNR and DNR were determined on growing MRC5 cells in 96-well dishes, incubated in the presence of increasing concentrations of the various compounds. After 72 hours, the cells are incubated for 48 hours in the absence of anthracycline and the cytotoxicity is determined by measurement of the cellular proteins by the Bradford technique. A range of 9 concentrations are used, ranging from 700 ⁇ g / ml to 0.0035 ⁇ g / ml, and each measurement represents an average and a standard deviation of 6 values. The experimental points are adjusted to a sigmoid curve which makes it possible to calculate the inflection point corresponding to the dose at which half of the cells survive (IC 50 ).
- Figure 13 illustrates that the IC 50 of the DNR is 0.010 ⁇ 0.006 ⁇ g / ml.
- the IC 50 is 1.78 ⁇ 0.23 ⁇ g / ml.
- the IC 50 is 23.14 ⁇ 4.81 ⁇ g / ml.
- Leu-DNR and ⁇ -Ala-Leu-Ala-Leu-DNR are therefore respectively 172 times and 2230 times less cytotoxic than DNR for fibroblastic cells MRC5 maintained in growth for 72 hours in the presence of anthracyclines.
- the precursor of DNR is much less toxic than the parent compound. It remains to be determined whether this decrease in toxicity observed in vitro is also observed in vivo.
- the acute toxicity of ⁇ -Ala-Leu-Ala-Leu-DNR was compared to that of daunorubicin in mice.
- the determination of the lethal dose 50 (lethal dose for 50% of the animals or LD 50 ) occupies an important place. Despite the fact that it does not represent a biological constant, it gives indications on the acute toxicity of the injected product.
- the LD 50 is a simple test where increasing amounts of the product to be tested are administered intravenously (iv) in a single injection and intraperitoneally (ip) in 5 injections, one injection per day for 5 consecutive days. The mortality of the animals is monitored as a function of time.
- the LD 50 value is obtained by linear regression of the percentage of mortality (on a probit scale) according to the logarithm of the dose administered (OK Chan and AW Hayes, Principles and methods for acute toxici ty and eye irri tancy, in Principles and methods of toxicology, second edition. Ed. by A W. Hayes. Raven Press. New York, USA (1989), pp. 169-220; D. Deprez -De Campeneere and A. Trouet. DNA-Anthracycline Complexes. I.
- the injections were carried out systematically in the morning (single injection into the caudal vein for iv and injections 5 consecutive days in the peritoneum for ip), using 1.0 ml syringes and needles 30G (iv) and 27G (ip) sterile. All animal handling was carried out with gloves and animal maintenance was carried out systematically every week.
- ⁇ -Ala-Leu-Ala-Leu-DNR was injected i.v. at doses of 30, 60 and 120 mg / kg and i.p. at total doses of 10, 15, 20, 25, 30, 45 and 60 mg / kg.
- ⁇ -Ala-Leu-Ala-Leu-DNR was reinjected intravenously at total doses of 30 and 60 mg / kg in one and two consecutive injections at 30 mg / kg respectively.
- the solutions of ⁇ -Ala-Leu-Ala-Leu-DNR and DNR were carried out in physiological NaCl so that the volume injected corresponds to 0.1 ml per 10 grams of mouse. The concentrations of the solutions were checked by spectrophotometry.
- mice From the day of the injections (D0), the mice were followed clinically, with a daily record of the dead mice. The weight of the mice was measured almost daily. The observation period was extended beyond the month, in order to better identify signs of late toxicity. At the end of the study, the surviving mice were sacrificed, according to the standards of animal experimentation (DB McGregor. Ethics in experiments on animais, in Experiments in toxicology, first edition. Ed. By D. Anderson and DM Conning The Royal Society of Chemistry and The Universities Press. Harbor, Ireland (1988), pp. 512-522).
- a significant toxicity is observed as a function of the concentration, toxicity which is manifested by the mortality of the mice, from day 7 at the dose of 3.5 mg / kg (1 out of 7 dead mice), from day 9 at the dose of 3.0 mg / kg (2 out of 7 dead mice) and from day 11 at the doses of 2.5 and 2.0 mg / kg (respectively 2 and 1 out of 7 dead mice).
- FIG. 15 indicates that, whatever the dose administered, the mice show a weight loss which reaches 30% of the initial weight. This weight loss is generally irreversible, except for a mouse treated with 2.5 mg / kg, which recovered its initial weight on day 30.
- the cells of human mammary carcinoma MCF7 / 6 and of the human fibroblast line MRC5 were incubated in the presence of ⁇ -Ala-Leu-Ala-Leu-DOX at a concentration of 10 ⁇ g eq. DOX / ml.
- the accumulation of the prodrugs and of their fluorescent metabolites was determined by HPLC after extraction of the products at basic pH, according to a method perfected in the laboratory.
- the accumulations, expressed in ⁇ g / mg of cellular proteins, were compared with those of DOX and L-Leu-DOX.
- the metabolites were identified by determining the retention times of reference products synthesized in the laboratory.
- DOX mainly accumulates in MCF7 / 6 cells essentially in unchanged form, and after 6 hours, an intracellular level of 6.9 ⁇ g / mg of cellular proteins is reached (Figure 23).
- Leu-DOX and ⁇ -Ala-Leu-Ala-Leu-DOX accumulate 6 times and 69 times respectively less than DOX after 6 hours. Intracellularly, the DOX levels are 31 times lower after incubation of the cells in the presence of ⁇ -Ala-Leu-Ala-Leu-DOX ( Figures 24 and 25).
- L-Leu-DOX accumulates at lower rates, the accumulation reaching 1.4 ⁇ g / mg of cellular proteins.
- the main metabolite is DOX (0.3 ⁇ g / mg of cellular proteins) ( Figure 27).
- ⁇ -Ala-Leu-Ala-Leu-DOX accumulates 112 times less than DOX after 6 hours. Intracellularly, the DOX levels are 1100 times lower after incubation of the cells in the presence of ⁇ -Ala-Leu-Ala-Leu-DOX (FIG. 28).
- the cytotoxicities of ⁇ -Ala-Leu-Ala-Leu-DOX, L-Leu-DOX and DOX were determined on MCF7 / 6 and MRC5 cells growing in 96-well dishes, incubated in the presence of increasing concentrations of the various compounds. After 72 hours, the cells are incubated for 48 hours in the absence of anthracycline and the cytotoxicity is determined by measurement of the cellular proteins by the Bradford technique. A range of 9 concentrations are used, ranging from 700 ⁇ g / ml to 0.0035 ⁇ g / ml, and each measurement represents an average and a standard deviation of 6 values. The experimental points are adjusted to a sigmoid curve which makes it possible to calculate the inflection point corresponding to the dose at which half of the cells survive (IC 50 ).
- the table in Example 12 shows the IC 50 values which are 0.0025, 0.020 and 3.0 ⁇ g / ml respectively for DOX, L-Leu-DOX and ⁇ -Ala-Leu-Ala- Leu- DOX for MCF7 / 6 human breast carcinoma cells.
- the values are 0.018, 0.30 and 120 ⁇ g / ml respectively.
- Leu-Ala-Leu-DOX are respectively 8 times and 1000 times less cytotoxic as DOX for fibroblast cells of human mammary carcinoma MCF7 / 6 maintained in growth for 72 hours in the presence of anthracyclines.
- Leu-DOX and ⁇ -Ala- Leu-Ala-Leu-DOX are respectively 17 times and 6700 times less cytotoxic than DOX for cells maintained in growth for 72 hours in the presence of anthracyclines .
- ⁇ -Ala-Leu-Ala-Leu-DOX is 40 times more toxic for MCF7 tumor cells than for MRC5 non-tumor cells. This is to be related to the higher intracellular levels of DOX which have been observed in MCF7 cells incubated in the presence of ⁇ -Ala-Leu-Ala-Leu-DOX (FIGS. 29 and 30).
- the compound is generally characterized by greater activity on solid tumor models (for example by injection of tumor cells subcutaneously) than on "leukemic" type models obtained after intravenous injection of tumor cells.
- the hydrolases they secrete will be immediately diluted in the blood stream.
- DOX in athymic mice to which a human mammary tumor has been implanted MCF7 / 6 reduces the evolution of the cancerous tumor (FIG. 31) without significantly affecting the average weight of the treated mice (FIG. 32).
- COUM is a metalloprotease inhibitable by metal chelators such as EDTA and requires the cobalt ion for its activity. Its optimum pH is between 7.5 and 8.0, which excludes that it is a cathepsin.
- FIG. 33 represents the measurement of the expression of coumarin in test tubes comprising the compound according to the invention in homogenates of tumor cells (of cancer of the lung, of the breast, of the ovaries, ...), of cells transformed (normal immortalized but non-cancerous cell line) as well as normal cells (fibroblasts and muscle cells).
- the compound according to the invention can be included in a diagnostic and / or assay device comprising various reagents well known to those skilled in the art.
- the diagnostic device of the invention can be used in a diagnostic and / or hystological or biochemical assay method comprising the removal from a patient of tissues, cells or physiological fluid, bringing them into contact with the compound according to the invention under conditions allowing the expression of the free marker (possibly involving one or more intermediate reagents) and the detection and / or quantification of the marker released.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Pharmacology & Pharmacy (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Genetics & Genomics (AREA)
- Crystallography & Structural Chemistry (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Immunology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Hydrogenated Pyridines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Multicomponent Fibers (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Abstract
Description
Claims
Priority Applications (14)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CA2203622A CA2203622C (fr) | 1994-08-19 | 1995-08-21 | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
DE69535665T DE69535665T2 (de) | 1994-08-19 | 1995-08-21 | Konjugate enthaltend ein antitumorales mittel und deren verwendung |
US08/793,910 US5962216A (en) | 1994-08-19 | 1995-08-21 | Tumor-activated prodrug compounds and treatment |
DK95928905T DK0769967T3 (da) | 1994-08-19 | 1995-08-21 | Konjugater der omfatter et antitumormiddel, og anvendelse heraf |
SI9530732T SI0769967T1 (sl) | 1994-08-19 | 1995-08-21 | Konjugati vsebujoäśi protitumorna sredstva in njihova uporaba |
AU32486/95A AU694546C (en) | 1994-08-19 | 1995-08-21 | Compounds, pharmaceutical composition and diagnostic device comprising same and their use |
NZ291368A NZ291368A (en) | 1994-08-19 | 1995-08-21 | A compound comprising a marker or a therapeutic agent linked to a ligand containing amino acids wherein the marker or agent is cleaved from the ligand to permit entry into the cell of the marker or agent, medicaments for treating tumours; diagnostic devices |
JP50766296A JP4157600B2 (ja) | 1994-08-19 | 1995-08-21 | 化合物、製剤用組成物及びこれらを含む診断装置とこれらの利用 |
EP95928905A EP0769967B1 (fr) | 1994-08-19 | 1995-08-21 | Conjugues comprenant un agent antitumoral et leur utilisation |
MXPA/A/1997/001283A MXPA97001283A (en) | 1994-08-19 | 1997-02-18 | Compounds, pharmaceutical composition and diagnostic device containing them and its |
NO19970748A NO324045B1 (no) | 1994-08-19 | 1997-02-18 | Forbindelser, farmasoytisk blanding og den anvendelse og diagnostisk anordning som omfatter forbindelsene |
US10/012,576 US7037898B2 (en) | 1994-08-19 | 2001-11-09 | Tumor-activated prodrug compounds and treatment |
US11/370,290 US7390629B2 (en) | 1994-08-19 | 2006-03-08 | Tumor-activated prodrug compounds and treatment |
US12/157,363 US7951772B2 (en) | 1994-08-19 | 2008-06-10 | Tumor-activated prodrug compounds and treatment |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
BE9400751 | 1994-08-19 | ||
BE9400751A BE1008580A3 (fr) | 1994-08-19 | 1994-08-19 | Prodrogues, composition pharmaceutiques les comprenant et leur utilisation. |
BE9400752A BE1008581A3 (fr) | 1994-08-19 | 1994-08-19 | Prodrogues, composition pharmaceutique les comprenant et leur utilisation. |
BE9400752 | 1994-08-19 |
Related Child Applications (3)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US08793910 A-371-Of-International | 1995-08-21 | ||
US08/793,910 A-371-Of-International US5962216A (en) | 1994-08-19 | 1995-08-21 | Tumor-activated prodrug compounds and treatment |
US09/298,330 Continuation US6342480B1 (en) | 1994-08-19 | 1999-04-23 | Tumor-activated prodrug compounds and treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1996005863A1 true WO1996005863A1 (fr) | 1996-02-29 |
Family
ID=25662908
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/BE1995/000076 WO1996005863A1 (fr) | 1994-08-19 | 1995-08-21 | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
Country Status (14)
Country | Link |
---|---|
US (5) | US5962216A (fr) |
EP (2) | EP1880737A1 (fr) |
JP (2) | JP4157600B2 (fr) |
AT (1) | ATE380559T1 (fr) |
AU (1) | AU694546C (fr) |
CA (1) | CA2203622C (fr) |
DE (1) | DE69535665T2 (fr) |
DK (1) | DK0769967T3 (fr) |
ES (1) | ES2297832T3 (fr) |
NO (1) | NO324045B1 (fr) |
NZ (1) | NZ291368A (fr) |
PT (1) | PT769967E (fr) |
SI (1) | SI0769967T1 (fr) |
WO (1) | WO1996005863A1 (fr) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1998002451A1 (fr) * | 1996-07-16 | 1998-01-22 | Novo Nordisk A/S | Oligopeptides transporteurs |
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5998362A (en) * | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
WO2000033888A2 (fr) | 1998-12-11 | 2000-06-15 | Coulter Pharmaceutical, Inc. | Composes de promedicaments et procede de preparation |
US6127333A (en) * | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
WO2001091798A2 (fr) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
WO2001095945A2 (fr) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Composes de promedicament a clivage enzymatique |
WO2001095943A2 (fr) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Composes de promedicaments contenant de l'isoleucine |
WO2002000263A2 (fr) * | 2000-06-14 | 2002-01-03 | Medarex, Inc. | Composes de tripeptide pour promedicaments |
US6355611B1 (en) | 1999-10-27 | 2002-03-12 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6844318B2 (en) | 2000-03-15 | 2005-01-18 | Bristol Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
FR2858936A1 (fr) * | 2003-08-22 | 2005-02-25 | Diatos | Potentialisation de l'activation de prodrogues de haut poids moleculaire |
US6897034B2 (en) | 2001-06-11 | 2005-05-24 | Medarex, Inc. | CD10-activated prodrug compounds |
WO2007105027A1 (fr) * | 2006-03-10 | 2007-09-20 | Diatos | Médicaments anticancéreux conjugués à un anticorps au moyen d'un lieur dissociable par une enzyme |
WO2008005942A2 (fr) * | 2006-06-30 | 2008-01-10 | The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. | Sondes susceptibles d'être activées et procédés d'utilisation |
US7402556B2 (en) * | 2000-08-24 | 2008-07-22 | Medarex, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
EP2075256A2 (fr) | 2002-01-14 | 2009-07-01 | William Herman | Ligands ciblés |
WO2012109624A2 (fr) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Complexes plurispécifiques monovalents et multivalents et leurs utilisations |
WO2012162561A2 (fr) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Complexes plurispécifiques multivalents et monovalents, et leurs utilisations |
US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
US9169321B2 (en) | 2007-08-22 | 2015-10-27 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US9453078B2 (en) | 2009-01-12 | 2016-09-27 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
WO2022043256A1 (fr) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Combinaisons synergiques de médicaments anticancéreux liés à une fraction tétrapeptidique et d'agents immunothérapeutiques |
WO2022136586A1 (fr) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
WO2022167664A1 (fr) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
Families Citing this family (41)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6517824B1 (en) * | 1990-05-14 | 2003-02-11 | University Of Medicine & Denistry Of New Jersey | Polymer compositions comprising antifibrotic agents, and methods of treatment, pharmaceutical compositions, and methods of preparation therefor |
WO1996005863A1 (fr) * | 1994-08-19 | 1996-02-29 | La Region Wallonne | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
US6174858B1 (en) | 1998-11-17 | 2001-01-16 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
WO2001024763A2 (fr) | 1999-10-01 | 2001-04-12 | Immunogen, Inc. | Compositions et methodes de traitement du cancer utilisant des immunoconjugues et des agents chimiotherapeutiques |
GB9924759D0 (en) | 1999-10-19 | 1999-12-22 | Merck Sharp & Dohme | Process for preparing peptide intermediates |
US20040014652A1 (en) * | 2000-06-01 | 2004-01-22 | Andre Trouet | Tumor activated prodrug compounds and methods of making and using the same |
ATE413164T1 (de) | 2000-11-09 | 2008-11-15 | Neopharm Inc | Sn-38-lipidkomplexe und verfahren zu ihrer verwendung |
CA2428971A1 (fr) * | 2000-11-14 | 2003-05-01 | New River Pharmaceuticals Inc. | Conjugues d'un agent therapeutique et d'un porteur peptidique |
WO2002060488A1 (fr) * | 2001-01-30 | 2002-08-08 | Universite Catholique De Louvain | Composes antitumoraux |
GB0105929D0 (en) * | 2001-03-09 | 2001-04-25 | Btg Int Ltd | Physiologically activated prodrugs |
WO2003030864A1 (fr) | 2001-05-29 | 2003-04-17 | Neopharm, Inc. | Formulation liposomale d'irinotecan |
US6989452B2 (en) * | 2001-05-31 | 2006-01-24 | Medarex, Inc. | Disulfide prodrugs and linkers and stabilizers useful therefor |
GB0310593D0 (en) * | 2003-05-08 | 2003-06-11 | Leuven K U Res & Dev | Peptidic prodrugs |
WO2005072061A2 (fr) | 2004-02-02 | 2005-08-11 | Biosight Ltd. | Remedes conjugues de therapie et diagnostic du cancer |
WO2005086951A2 (fr) * | 2004-03-10 | 2005-09-22 | Threshold Pharmaceuticals, Inc. | Agents anticancereux actives par l'hypoxie |
JP4658507B2 (ja) * | 2004-03-31 | 2011-03-23 | 竹本容器株式会社 | 自開式キャップ機構 |
US7691962B2 (en) * | 2004-05-19 | 2010-04-06 | Medarex, Inc. | Chemical linkers and conjugates thereof |
NZ550934A (en) * | 2004-05-19 | 2010-05-28 | Medarex Inc | Chemical linkers and conjugates thereof |
JP4433918B2 (ja) * | 2004-07-15 | 2010-03-17 | コニカミノルタエムジー株式会社 | 画像形成方法 |
KR100651728B1 (ko) * | 2004-11-10 | 2006-12-06 | 한국전자통신연구원 | 정착기를 갖는 전자 소자용 화합물 및 이를 포함하는 전자소자와 이들의 제조 방법 |
NZ556661A (en) * | 2005-02-18 | 2010-10-29 | Medarex Inc | Human monoclonal antibodies to prostate specific membrance antigen (PSMA) |
US7714016B2 (en) * | 2005-04-08 | 2010-05-11 | Medarex, Inc. | Cytotoxic compounds and conjugates with cleavable substrates |
US20070060534A1 (en) * | 2005-06-30 | 2007-03-15 | Threshold Pharmaceuticals, Inc. | Anthracycline analogs |
US20080279868A1 (en) * | 2005-09-26 | 2008-11-13 | Medarex, Inc. | Antibody-Drug Conjugates and Methods of Use |
ES2375843T3 (es) | 2005-10-26 | 2012-03-06 | Medarex, Inc. | Procedimientos y compuestos para la preparación de an�?logos de cc-1065. |
WO2007059404A2 (fr) | 2005-11-10 | 2007-05-24 | Medarex, Inc. | Composes et conjugues cytotoxiques |
US7718044B2 (en) * | 2006-09-11 | 2010-05-18 | Seagate Technology Llc | Method for controlling shaft coating taper |
TWI412367B (zh) | 2006-12-28 | 2013-10-21 | Medarex Llc | 化學鏈接劑與可裂解基質以及其之綴合物 |
US8664407B2 (en) | 2007-02-21 | 2014-03-04 | Medarex, LLC | Chemical linkers with single amino acids and conjugates thereof |
FR2960153B1 (fr) * | 2010-05-20 | 2012-08-17 | Centre Nat Rech Scient | Nouveaux bras autoreactifs et prodrogues les comprenant |
CN105849086B (zh) | 2012-11-24 | 2018-07-31 | 杭州多禧生物科技有限公司 | 亲水性链接体及其在药物分子和细胞结合分子共轭反应上的应用 |
EP2781919A1 (fr) | 2013-03-19 | 2014-09-24 | Roche Diagniostics GmbH | Procédé/dispositif permettant de générer une valeur corrigée de concentration d'un analyte dans un échantillon d'un fluide corporel |
US10464955B2 (en) | 2014-02-28 | 2019-11-05 | Hangzhou Dac Biotech Co., Ltd. | Charged linkers and their uses for conjugation |
AU2015242213A1 (en) | 2015-07-12 | 2018-03-08 | Hangzhou Dac Biotech Co., Ltd | Bridge linkers for conjugation of cell-binding molecules |
US9839687B2 (en) | 2015-07-15 | 2017-12-12 | Suzhou M-Conj Biotech Co., Ltd. | Acetylenedicarboxyl linkers and their uses in specific conjugation of a cell-binding molecule |
US12071450B2 (en) | 2015-12-03 | 2024-08-27 | Biosight Ltd. | Salts of conjugates for cancer therapy |
US12064445B2 (en) | 2015-12-03 | 2024-08-20 | Biosight Ltd. | Cytarabine conjugates for cancer therapy |
JP2018535987A (ja) | 2015-12-03 | 2018-12-06 | バイオサイト リミテッド | 癌療法のためのコンジュゲートの塩 |
BR112018011177A2 (pt) | 2015-12-03 | 2018-11-21 | Biosight Ltd | conjugados de citarabina para terapia de câncer |
CN106074556B (zh) * | 2016-06-14 | 2018-11-16 | 河南师范大学 | L型胞嘧啶丙氨酸在制备抗癌药物中的应用 |
US20210308277A1 (en) | 2016-11-14 | 2021-10-07 | Hangzhou Dac Biotech Co., Ltd. | Conjugation linkers, cell binding molecule-drug conjugates containing the linkers, methods of making and uses such conjugates with the linkers |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE869485A (fr) * | 1978-08-03 | 1978-12-01 | Inst Internat De Pathologie Ce | Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent |
BE882541A (fr) * | 1980-03-31 | 1980-07-16 | Inst Internat De Pathologie Ce | Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent |
US4296105A (en) * | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
EP0041935A1 (fr) * | 1980-06-10 | 1981-12-16 | OMNICHEM Société anonyme | Dérivés n-(vinblastinoyl-23) d'acides aminés et de peptides ainsi que leur préparation |
EP0044090A2 (fr) * | 1978-10-02 | 1982-01-20 | Merck & Co. Inc. | Agents thérapeutiques détergents lysosomotropiques, compositions qui les contiennent et leur utilisation |
EP0126685A1 (fr) * | 1983-05-16 | 1984-11-28 | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | Nouveaux dérivés acylés hydrosolubles de peptides ou d'amino-acides, leur préparation et leur application |
EP0208615A1 (fr) * | 1985-07-04 | 1987-01-14 | Ire-Celltarg S.A. | Anticorps utiles comme agents de pilotage et conjugués les incorporant |
Family Cites Families (26)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4277466A (en) * | 1978-08-29 | 1981-07-07 | Institut International De Pathologie Cellulaire Et Moleculaire | Complexes of DNA and esters derived from daunorubicine, their preparation and use |
US4719312A (en) * | 1978-10-02 | 1988-01-12 | Merck & Co., Inc. | Lysosometropic detergent therapeutic agents |
WO1981001145A1 (fr) | 1979-10-18 | 1981-04-30 | Univ Illinois | Medicaments "pro-drugs" pouvant etre actives par des enzymes hydrolytiques |
EP0037388B1 (fr) * | 1980-03-31 | 1984-12-12 | Institut International De Pathologie Cellulaire Et Moleculaire | Formes pharmaceutiques, leur préparation et les compositions qui les contiennent |
US4376765A (en) * | 1980-03-31 | 1983-03-15 | Institut International De Pathologie Cellulaire Et Moleculaire | Medicaments, their preparation and compositions containing same |
US4639456A (en) * | 1980-06-10 | 1987-01-27 | Omnichem S.A. | Vinblastin-23-oyl amino acid derivatives |
US4671958A (en) * | 1982-03-09 | 1987-06-09 | Cytogen Corporation | Antibody conjugates for the delivery of compounds to target sites |
EP0124502B1 (fr) * | 1983-04-29 | 1991-06-12 | OMNICHEM Société anonyme | Nouveaux conjugués de la vinblastine et de ses dérivés, procédé pour leur préparation et compositions pharmaceutiques contenant ces conjugués |
EP0126344A2 (fr) | 1983-05-20 | 1984-11-28 | Abbott Laboratories | Esters tripeptidiques d'agents thérapeutiques |
JPS60233642A (ja) * | 1984-05-07 | 1985-11-20 | Fuji Photo Film Co Ltd | 写真画像の形成方法 |
AU618029B2 (en) | 1987-11-02 | 1991-12-12 | Imperial Chemical Industries Plc | Polypeptide compounds |
FR2626882B1 (fr) * | 1988-02-08 | 1991-11-08 | Ire Celltarg Sa | Conjugues de derives de vinca comportant une chaine detergente en position c-3 |
DE3841764A1 (de) | 1988-12-12 | 1990-06-13 | Basf Ag | Neue tnf-peptide |
US5220001A (en) * | 1989-10-25 | 1993-06-15 | Zaidan Hojim Biseibutsu Dong-A Pharm Co. | Anthracycline glycoside derivatives |
FI91777C (fi) * | 1990-04-02 | 1994-08-10 | Elomit Oy | Menetelmä plasmiiniaktiivisuuden määrittämiseksi |
US5618790A (en) * | 1990-10-05 | 1997-04-08 | Queen's University At Kingston | Protease mediated drug delivery system |
JPH06510529A (ja) | 1991-08-05 | 1994-11-24 | イゲン,インコーポレーテッド | 目標とする触媒性たんぱく質により活性化されるプロドラッグ |
WO1994007518A1 (fr) | 1992-09-25 | 1994-04-14 | Abbott Laboratories | Ligands de recepteurs d'anaphylatoxine contenant des restes lipophiles |
EP0679153A4 (fr) | 1993-01-14 | 1996-05-15 | Magainin Pharma | Acides amines et peptides a terminaisons modifiees. |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
US5599686A (en) * | 1994-06-28 | 1997-02-04 | Merck & Co., Inc. | Peptides |
WO1996005863A1 (fr) * | 1994-08-19 | 1996-02-29 | La Region Wallonne | Composes, composition pharmaceutique et dispositif de diagnostic les comprenant et leur utilisation |
US5659061A (en) * | 1995-04-20 | 1997-08-19 | Drug Innovation & Design, Inc. | Tumor protease activated prodrugs of phosphoramide mustard analogs with toxification and detoxification functionalities |
CA2370245A1 (fr) | 1999-05-14 | 2000-11-23 | Boehringer Ingelheim Pharmaceuticals, Inc. | Composes de promedicaments anti-tumoraux actives par des enzymes |
WO2001028593A2 (fr) | 1999-10-19 | 2001-04-26 | Merck & Co., Inc. | Processus de preparation de conjugues convenant pour le traitement du cancer de la prostate |
EP1228089A2 (fr) | 1999-10-27 | 2002-08-07 | Merck & Co., Inc. | Sel d'un conjugue utile pour traiter le cancer de la prostate |
-
1995
- 1995-08-21 WO PCT/BE1995/000076 patent/WO1996005863A1/fr active IP Right Grant
- 1995-08-21 NZ NZ291368A patent/NZ291368A/en not_active IP Right Cessation
- 1995-08-21 AT AT95928905T patent/ATE380559T1/de active
- 1995-08-21 DK DK95928905T patent/DK0769967T3/da active
- 1995-08-21 DE DE69535665T patent/DE69535665T2/de not_active Expired - Lifetime
- 1995-08-21 ES ES95928905T patent/ES2297832T3/es not_active Expired - Lifetime
- 1995-08-21 JP JP50766296A patent/JP4157600B2/ja not_active Expired - Lifetime
- 1995-08-21 SI SI9530732T patent/SI0769967T1/sl unknown
- 1995-08-21 AU AU32486/95A patent/AU694546C/en not_active Expired
- 1995-08-21 US US08/793,910 patent/US5962216A/en not_active Expired - Lifetime
- 1995-08-21 CA CA2203622A patent/CA2203622C/fr not_active Expired - Lifetime
- 1995-08-21 EP EP07119790A patent/EP1880737A1/fr not_active Withdrawn
- 1995-08-21 PT PT95928905T patent/PT769967E/pt unknown
- 1995-08-21 EP EP95928905A patent/EP0769967B1/fr not_active Expired - Lifetime
-
1997
- 1997-02-18 NO NO19970748A patent/NO324045B1/no not_active IP Right Cessation
-
1999
- 1999-04-23 US US09/298,330 patent/US6342480B1/en not_active Expired - Lifetime
-
2001
- 2001-11-09 US US10/012,576 patent/US7037898B2/en not_active Expired - Fee Related
-
2006
- 2006-03-08 US US11/370,290 patent/US7390629B2/en not_active Expired - Fee Related
-
2007
- 2007-11-21 JP JP2007301893A patent/JP2008069175A/ja active Pending
-
2008
- 2008-06-10 US US12/157,363 patent/US7951772B2/en not_active Expired - Fee Related
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
BE869485A (fr) * | 1978-08-03 | 1978-12-01 | Inst Internat De Pathologie Ce | Nouveaux derives de la doxorubicine, leur preparation et les compositions qui les contiennent |
US4296105A (en) * | 1978-08-03 | 1981-10-20 | Institut International De Pathologie Cellulaire Et Moleculaire | Derivatives of doxorubicine, their preparation and use |
EP0044090A2 (fr) * | 1978-10-02 | 1982-01-20 | Merck & Co. Inc. | Agents thérapeutiques détergents lysosomotropiques, compositions qui les contiennent et leur utilisation |
BE882541A (fr) * | 1980-03-31 | 1980-07-16 | Inst Internat De Pathologie Ce | Nouvelles formes pharmaceutiques leur preparation et les compositions qui les contiennent |
EP0041935A1 (fr) * | 1980-06-10 | 1981-12-16 | OMNICHEM Société anonyme | Dérivés n-(vinblastinoyl-23) d'acides aminés et de peptides ainsi que leur préparation |
EP0126685A1 (fr) * | 1983-05-16 | 1984-11-28 | Etablissement Public dit: CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS) | Nouveaux dérivés acylés hydrosolubles de peptides ou d'amino-acides, leur préparation et leur application |
EP0208615A1 (fr) * | 1985-07-04 | 1987-01-14 | Ire-Celltarg S.A. | Anticorps utiles comme agents de pilotage et conjugués les incorporant |
Non-Patent Citations (12)
Title |
---|
CHEMICAL ABSTRACTS, vol. 107, no. 15, 12 October 1987, Columbus, Ohio, US; abstract no. 127965, WHALLEY, E. T.: "Receptors mediating the increase in vascular permeability to kinins: comparative studies in rat, guinea pig and rabbit" * |
CHEMICAL ABSTRACTS, vol. 121, no. 7, 15 August 1994, Columbus, Ohio, US; abstract no. 79924, KENNETT, C. N. ET AL: "Comparative histochemical, biochemical and immunocytochemical studies of cathepsin B in human gingiva" * |
CHEMICAL ABSTRACTS, vol. 97, no. 18, 1 November 1982, Columbus, Ohio, US; abstract no. 150635, MASQUELIER, M. ET AL: "Antitumor activity of daunorubicin linked to proteins: biological and antitumor properties of peptidic derivatives of daunorubicin used as intermediates" * |
CURR. CHEMOTHER. IMMUNOTHER., PROC. INT. CONGR. CHEMOTHER., 12TH (1982), MEETING DATE 1981, VOLUME 2, 1428-30. EDITOR(S): PERITI, PIERO;GIALDRONI GRASSI, GIULIANA. PUBLISHER: AM. SOC. MICROBIOL., WASHINGTON, D. C. CODEN: 48HGAR * |
CURR. CHEMOTHER. IMMUNOTHER., PROC. INT. CONGR. CHEMOTHER., 12TH (1982), MEETING DATE 1981, VOLUME 2, 1430-2. EDITOR(S): PERITI, PIERO;GIALDRONI GRASSI, GIULIANA. PUBLISHER: AM. SOC. MICROBIOL., WASHINGTON, D. C. CODEN: 48HGAR * |
DATABASE CHEMABS CHEMICAL ABSTRACTS SERVICE, COLUMBUS, OHIO, US; BAURAIN, R. ET AL: "Antitumor activity of daunorubicin linked to proteins: lysosomal hydrolysis and antitumor activity of conjugates prepared with peptidic spacer arms" * |
J. PERIODONTAL RES. (1994), 29(3), 203-13 CODEN: JPDRAY;ISSN: 0022-3484 * |
M. MASQUELIER ET AL.: "AMINO ACIDS AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 1. SYNTHESIS, PHYSICOCHEMICAL PROPERTIES , AND LYSOSOMAL DIGESTION.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, WASHINGTON US, pages 1166 - 1170 * |
MARRE, ANNE DE ET AL: "Evaluation of the hydrolytic and enzymic stability of macromolecular Mitomycin C derivatives", J. CONTROLLED RELEASE (1994), 31(1), 89-97 CODEN: JCREEC;ISSN: 0168-3659 * |
NAUNYN-SCHMIEDEBERG'S ARCH. PHARMACOL. (1987), 336(1), 99-104 CODEN: NSAPCC;ISSN: 0028-1298 * |
R. BAURAIN ET AL.: "AMINO ACID AND DIPEPTIDE DERIVATIVES OF DAUNORUBICIN. 2. CELLULAR PHARMACOLOGY AND ANTITUMOR ACTIVITY ON L1210 LEUKEMIC CELLS IN VITRO AND IN VIVO.", JOURNAL OF MEDICINAL CHEMISTRY, vol. 23, WASHINGTON US, pages 1171 - 1174 * |
SEITZ, DAVID E. ET AL: "Synthesis and chemical properties of a series of doxorubicin enaminomalonyl-. beta.- alanine derivatives", TETRAHEDRON LETT. (1995), 36(9), 1413-16 CODEN: TELEAY;ISSN: 0040-4039 * |
Cited By (53)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5866679A (en) * | 1994-06-28 | 1999-02-02 | Merck & Co., Inc. | Peptides |
US6143864A (en) * | 1994-06-28 | 2000-11-07 | Merck & Co., Inc. | Peptides |
US6130204A (en) * | 1995-10-06 | 2000-10-10 | Merck & Co., Inc. | Peptides |
WO1998002451A1 (fr) * | 1996-07-16 | 1998-01-22 | Novo Nordisk A/S | Oligopeptides transporteurs |
US5998362A (en) * | 1996-09-12 | 1999-12-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US5948750A (en) * | 1996-10-30 | 1999-09-07 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6127333A (en) * | 1997-07-10 | 2000-10-03 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
US6391305B1 (en) | 1997-09-10 | 2002-05-21 | Merck & Co., Inc. | Conjugates useful in the treatment of prostate cancer |
WO2000033888A2 (fr) | 1998-12-11 | 2000-06-15 | Coulter Pharmaceutical, Inc. | Composes de promedicaments et procede de preparation |
US8034787B2 (en) | 1998-12-11 | 2011-10-11 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
US7425541B2 (en) | 1998-12-11 | 2008-09-16 | Medarex, Inc. | Enzyme-cleavable prodrug compounds |
WO2000033888A3 (fr) * | 1998-12-11 | 2001-11-08 | Coulter Pharm Inc | Composes de promedicaments et procede de preparation |
AU773420B2 (en) * | 1998-12-11 | 2004-05-27 | Medarex, Inc. | Prodrug compounds and process for preparation thereof |
US6355611B1 (en) | 1999-10-27 | 2002-03-12 | Merck & Co., Inc. | Salt form of a conjugate useful in the treatment of prostate cancer |
US6844318B2 (en) | 2000-03-15 | 2005-01-18 | Bristol Myers Squibb Pharma Company | Peptidase-cleavable, targeted antineoplastic drugs and their therapeutic use |
WO2001091798A2 (fr) * | 2000-06-01 | 2001-12-06 | Universite Catholique De Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
WO2001091798A3 (fr) * | 2000-06-01 | 2002-12-05 | Univ Catholique Louvain | Composes de promedicaments a activation tumorale et procedes de fabrication et d'utilisation de ces derniers |
US7214663B2 (en) | 2000-06-14 | 2007-05-08 | Medarex, Inc. | Tripeptide prodrug compounds |
US7696313B2 (en) | 2000-06-14 | 2010-04-13 | Medarex, Inc. | Prodrug compounds with isoleucine |
WO2001095945A3 (fr) * | 2000-06-14 | 2002-08-15 | Corixa Corp | Composes de promedicament a clivage enzymatique |
WO2002000263A3 (fr) * | 2000-06-14 | 2002-08-15 | Corixa Corp | Composes de tripeptide pour promedicaments |
WO2001095945A2 (fr) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Composes de promedicament a clivage enzymatique |
US7816317B2 (en) | 2000-06-14 | 2010-10-19 | Medarex, Inc. | Tripeptide prodrug compounds |
US7329507B2 (en) | 2000-06-14 | 2008-02-12 | Medarex, Inc. | Prodrug compounds with isoleucine |
WO2001095943A2 (fr) * | 2000-06-14 | 2001-12-20 | Medarex, Inc. | Composes de promedicaments contenant de l'isoleucine |
US7115573B2 (en) * | 2000-06-14 | 2006-10-03 | Medarex, Inc. | Prodrug compounds with an isoleucine |
WO2002000263A2 (fr) * | 2000-06-14 | 2002-01-03 | Medarex, Inc. | Composes de tripeptide pour promedicaments |
WO2001095943A3 (fr) * | 2000-06-14 | 2002-08-29 | Corixa Corp | Composes de promedicaments contenant de l'isoleucine |
US7402556B2 (en) * | 2000-08-24 | 2008-07-22 | Medarex, Inc. | Prodrugs activated by plasmin and their use in cancer chemotherapy |
US7304032B2 (en) | 2001-06-11 | 2007-12-04 | Medarex, Inc. | CD-10 activated prodrug compounds |
US6897034B2 (en) | 2001-06-11 | 2005-05-24 | Medarex, Inc. | CD10-activated prodrug compounds |
EP2075256A2 (fr) | 2002-01-14 | 2009-07-01 | William Herman | Ligands ciblés |
WO2005021043A3 (fr) * | 2003-08-22 | 2006-06-15 | Diatos | Prodrogues a haut poids moleculaire |
WO2005021043A2 (fr) * | 2003-08-22 | 2005-03-10 | Diatos | Prodrogues a haut poids moleculaire |
FR2858936A1 (fr) * | 2003-08-22 | 2005-02-25 | Diatos | Potentialisation de l'activation de prodrogues de haut poids moleculaire |
WO2007105027A1 (fr) * | 2006-03-10 | 2007-09-20 | Diatos | Médicaments anticancéreux conjugués à un anticorps au moyen d'un lieur dissociable par une enzyme |
WO2008005942A2 (fr) * | 2006-06-30 | 2008-01-10 | The Govt. Of The Usa As Represented By The Secretary Of The Dept. Of Health And Human Services. | Sondes susceptibles d'être activées et procédés d'utilisation |
WO2008005942A3 (fr) * | 2006-06-30 | 2008-07-31 | Govt Of The Usa As Represented | Sondes susceptibles d'être activées et procédés d'utilisation |
US9169321B2 (en) | 2007-08-22 | 2015-10-27 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US11028162B2 (en) | 2007-08-22 | 2021-06-08 | The Regents Of The University Of California | Methods for manufacturing activatable binding polypeptides comprising matrix metalloprotease cleavable moieties |
US10077300B2 (en) | 2007-08-22 | 2018-09-18 | The Regents Of The University Of California | Activatable binding polypeptides and methods of identification and use thereof |
US9453078B2 (en) | 2009-01-12 | 2016-09-27 | Cytomx Therapeutics, Inc. | Modified antibody compositions, methods of making and using thereof |
US10059762B2 (en) | 2009-01-12 | 2018-08-28 | Cytomx Therapeutics, Inc. | Anti-EGFR activatable antibodies |
US10118961B2 (en) | 2009-01-12 | 2018-11-06 | Cytomx Therapeutics, Inc. | Modified antibody containing the cleavable peptide with the amino acid sequence TGRGPSWV |
US10875913B2 (en) | 2009-01-12 | 2020-12-29 | Cytomx Therapeutics, Inc. | Methods of treatment using activatable anti-EGFR antibodies |
US8399219B2 (en) | 2009-02-23 | 2013-03-19 | Cytomx Therapeutics, Inc. | Protease activatable interferon alpha proprotein |
US9644016B2 (en) | 2009-02-23 | 2017-05-09 | Cytomx Therapeutics, Inc. | Soluble notch receptor proproteins and methods of use thereof |
US10513549B2 (en) | 2009-02-23 | 2019-12-24 | Cytomx Therapeutics, Inc. | Cleavage-activatable interferon-alpha proprotein |
WO2012109624A2 (fr) | 2011-02-11 | 2012-08-16 | Zyngenia, Inc. | Complexes plurispécifiques monovalents et multivalents et leurs utilisations |
WO2012162561A2 (fr) | 2011-05-24 | 2012-11-29 | Zyngenia, Inc. | Complexes plurispécifiques multivalents et monovalents, et leurs utilisations |
WO2022043256A1 (fr) | 2020-08-23 | 2022-03-03 | Cobiores Nv | Combinaisons synergiques de médicaments anticancéreux liés à une fraction tétrapeptidique et d'agents immunothérapeutiques |
WO2022136586A1 (fr) | 2020-12-22 | 2022-06-30 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
WO2022167664A1 (fr) | 2021-02-07 | 2022-08-11 | Cobiores Nv | Composés comprenant une fraction tétrapeptidique |
Also Published As
Publication number | Publication date |
---|---|
JP2008069175A (ja) | 2008-03-27 |
PT769967E (pt) | 2008-02-18 |
US20020160943A1 (en) | 2002-10-31 |
US6342480B1 (en) | 2002-01-29 |
NO970748L (no) | 1997-04-10 |
MX9701283A (es) | 1997-09-30 |
AU694546C (en) | 2001-09-06 |
CA2203622C (fr) | 2011-11-01 |
US20060148682A1 (en) | 2006-07-06 |
NO970748D0 (no) | 1997-02-18 |
US7390629B2 (en) | 2008-06-24 |
NO324045B1 (no) | 2007-08-06 |
US7951772B2 (en) | 2011-05-31 |
EP0769967B1 (fr) | 2007-12-12 |
JPH10508291A (ja) | 1998-08-18 |
AU3248695A (en) | 1996-03-14 |
CA2203622A1 (fr) | 1996-02-29 |
SI0769967T1 (sl) | 2008-06-30 |
NZ291368A (en) | 1999-04-29 |
DE69535665T2 (de) | 2009-04-02 |
US5962216A (en) | 1999-10-05 |
EP0769967A1 (fr) | 1997-05-02 |
JP4157600B2 (ja) | 2008-10-01 |
DK0769967T3 (da) | 2008-03-31 |
US7037898B2 (en) | 2006-05-02 |
DE69535665D1 (de) | 2008-01-24 |
US20090137494A1 (en) | 2009-05-28 |
ATE380559T1 (de) | 2007-12-15 |
ES2297832T3 (es) | 2008-05-01 |
AU694546B2 (en) | 1998-07-23 |
EP1880737A1 (fr) | 2008-01-23 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP0769967B1 (fr) | Conjugues comprenant un agent antitumoral et leur utilisation | |
US8957016B2 (en) | Tumor activated prodrugs | |
US7041818B2 (en) | DDS compound and method for measurement thereof | |
JP4675028B2 (ja) | トリメチルロック型テトラパルテートプロドラッグ | |
US20240199695A1 (en) | Peptide compounds and peptide conjugates for the treatment of cancer through receptor-mediated chemotherapy | |
US9867884B2 (en) | Vascular delivery systems | |
DE102005009084A1 (de) | Proteinbindende Anthrazyklin-Peptid-Derivate und diese enthaltende Arzneimittel | |
EP3508221A1 (fr) | Conjugué photosensibilisateur-médicament ciblant les tumeurs, son procédé de préparation et composition pharmaceutique pour la prévention ou le traitement des tumeurs le contenant | |
WO2002043773A2 (fr) | Promedicaments propres aux tissus | |
HU217806B (hu) | Eljárás polimerhez kötött antraciklin-glikozidokat tartalmazó gyógyszerkészítmények előállítására | |
KR20150099655A (ko) | 벤조일옥시신남알데히드-폴리에틸렌글리콜 결합 마이셀에 아연 프로토포르피린을 담지한 pH 감응형 항암 전구약물 및 이의 제조방법 | |
JP6803589B2 (ja) | 抗腫瘍剤 | |
MXPA97001283A (en) | Compounds, pharmaceutical composition and diagnostic device containing them and its | |
JP2011527671A (ja) | ペプチド及び癌細胞中へのキャリヤーとしてのその使用 | |
BE1008580A3 (fr) | Prodrogues, composition pharmaceutiques les comprenant et leur utilisation. | |
EP4427762A1 (fr) | Trans-cyclooctène avec un lieur t amélioré | |
CN117715645A (zh) | 用于癌症治疗的药物组合物 | |
NZ731411A (en) | Pharmaceutical composition comprising modified hemoglobin-based therapeutic agent for cancer targeting treatment and diagnostic imaging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KE KG KP KR KZ LK LR LT LV MD MG MK MN MW MX NO NZ PL RO RU SD SG SI SK TJ TM TT UA UG US UZ VN |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 291368 Country of ref document: NZ |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/1997/001283 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1995928905 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 08793910 Country of ref document: US |
|
ENP | Entry into the national phase |
Ref document number: 2203622 Country of ref document: CA Kind code of ref document: A Ref document number: 2203622 Country of ref document: CA |
|
WWP | Wipo information: published in national office |
Ref document number: 1995928905 Country of ref document: EP |
|
WWG | Wipo information: grant in national office |
Ref document number: 1995928905 Country of ref document: EP |